<div class="hlFld-Fulltext">
<div xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="boxed-text-float" id="d3e510">
<div id="acd3e512" class="anchor-spacer"></div>
<h2 class="article-section__title section__title" id="d3e512">Clinical Perspective</h2>
<div id="acd3e517" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e517">What Is New?</h3>
<ul class="NLM_list-list_type-bullet">
<li><p class="inline">There
 is a spectrum of cardiovascular events in people with diabetes 
mellitus, with about twice the major adverse cardiovascular events rate 
in those with prior myocardial infarction/stroke versus those with risk 
factors alone.</p></li>
<li><p class="inline">Liraglutide consistently 
lowered the primary and expanded major adverse cardiovascular event 
outcomes in people with diabetes mellitus and atherosclerotic 
cardiovascular disease regardless of prior myocardial infarction/stroke 
history.</p></li>
<li><p class="inline">In people with diabetes mellitus with risk factors alone, liraglutide appeared safe but not superior to placebo.</p></li>
</ul>
<div id="acd3e538" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e538">What Are the Clinical Implications?</h3>
<ul class="NLM_list-list_type-bullet">
<li><p class="inline">Liraglutide
 is an effective antihyperglycemic agent for the reduction of 
cardiovascular events in people with diabetes mellitus who had a prior 
myocardial infarction or stroke or in those who have atherosclerotic 
cardiovascular disease but have not yet had a myocardial infarction or 
stroke.</p></li>
<li><p class="inline">In people with type 2 diabetes 
mellitus who only have risk factors, liraglutide is safe but, in the 
short term, is not associated with reductions in major adverse 
cardiovascular events.</p></li>
</ul>
</div>
<div id="acd3e556" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e556">Introduction</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Despite
 optimal medical therapy, morbidity and mortality from cardiovascular 
disease remain significantly higher in patients with diabetes mellitus 
compared with age- and sex-matched individuals without diabetes 
mellitus.<sup><a data-tab="pane-pcw-references" href="#R1%20R2%20R3" id="R1 R2 R3R" class="tab-link">1–3</a></sup>
 In fact, patients with diabetes mellitus and a prior ischemic 
cardiovascular event are at an especially high risk of recurrent events.<sup><a data-tab="pane-pcw-references" href="#R4%20R5%20R6" id="R4 R5 R6R" class="tab-link">4–6</a></sup> Although strides have been made with respect to a reduction in macrovascular and microvascular events in diabetes mellitus,<sup><a data-tab="pane-pcw-references" href="#R7" id="R7R" class="tab-link">7</a></sup> the rise in the prevalence of diabetes mellitus poses a substantial cardiovascular burden worldwide.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 LEADER trial (Liraglutide and Cardiovascular Outcomes in Type 2 
Diabetes) demonstrated a 13% significant relative risk reduction in 
major adverse cardiovascular events (MACE) with liraglutide versus 
placebo, both as add-on to standard-of-care treatment, in patients with 
type 2 diabetes mellitus (T2DM) and high cardiovascular risk.<sup><a data-tab="pane-pcw-references" href="#R8" id="R8R" class="tab-link">8</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Because
 the presence of myocardial infarction (MI) or stroke is one of the most
 important risk stratifiers in patients with diabetes mellitus and high 
cardiovascular risk,<sup><a data-tab="pane-pcw-references" href="#R1" id="R1R" class="tab-link">1</a>,<a data-tab="pane-pcw-references" href="#R9" id="R9R" class="tab-link">9</a></sup>
 it is important to evaluate the absolute and relative benefits of 
cardiovascular risk reduction approaches across the continuum of 
patients with diabetes mellitus with varying cardiovascular risk, 
ranging from history of MI/stroke to established atherosclerotic 
cardiovascular disease without a history of MI/stroke and cardiovascular
 risk factors alone.</p>
<div id="acd3e593" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e593">Methods</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 subject-level analysis data sets for the research presented in the 
publication are available from the corresponding author on reasonable 
request.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The design of the LEADER trial (Clinicaltrials.gov NCT01179048) has been described previously.<sup><a data-tab="pane-pcw-references" href="#R8" id="R8R" class="tab-link">8</a>,<a data-tab="pane-pcw-references" href="#R10" id="R10R" class="tab-link">10</a></sup>
 Briefly, LEADER was a randomized, double-blind, multicenter, 
placebo-controlled, cardiovascular outcomes trial. The trial protocol 
was reviewed and approved by the institutional review board or ethics 
committee at each participating center. All patients provided written 
informed consent before participation.</p>
<div id="acd3e611" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e611">Patients</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">In
 total, 9340 patients with T2DM with a glycohemoglobin level of ≥7.0% 
and high cardiovascular risk were randomly assigned to receive 
liraglutide 1.8 mg/d (or the maximum tolerated dose) or placebo, both as
 add-on to standard of care, and followed up for 3.5 to 5 years. 
Patients included were either &gt;50 years of age with established 
cardiovascular disease, defined by the protocol as coronary artery 
disease, cerebrovascular disease, peripheral artery disease, New York 
Heart Association class II or III heart failure, or chronic kidney 
disease (estimated glomerular filtration rate &lt;60 mL·min<sup>−1</sup>·1.73 m<sup>−2</sup>),
 or &gt;60 years of age with at least 1 additional cardiovascular risk 
factor (microalbuminuria or proteinuria, hypertension and left 
ventricular hypertrophy, left ventricular systolic or diastolic 
dysfunction, or an ankle-brachial index &lt;0.9).</p>
<div id="acd3e626" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e626">Risk Groups</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">In
 this post hoc analysis, we compared the incidence of the primary and 
secondary composite outcomes with liraglutide versus placebo in 3 
mutually exclusive clinically relevant risk groups. Risk groups were 
defined according to those with and without atherosclerotic disease and 
degree of disease: (1) patients with a history of MI/stroke, (2) 
patients with established atherosclerotic cardiovascular disease without
 MI/stroke (≥50% coronary artery stenosis, percutaneous coronary 
intervention or coronary artery bypass graft [CABG] surgery, angina 
pectoris with a positive stress imaging test and/or asymptomatic 
ischemia [but no MI], transient ischemic attack, ≥50% intracranial or 
carotid artery stenosis, and ≥50% peripheral artery stenosis by imaging 
or ankle-brachial index &lt;0.9), or (3) patients with cardiovascular 
risk factors alone (ie, those not meeting definitions for the former 
risk groups such as those with isolated chronic kidney disease, 
hypertension with left ventricular hypertrophy, New York Heart 
Association class II or III heart failure, and left ventricular systolic
 or diastolic dysfunction). This information was investigator-reported 
at randomization. The presence of stroke included both ischemic and 
hemorrhagic stroke.</p>
<div id="acd3e636" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e636">Outcomes</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 primary outcome was defined as the first occurrence of a MACE (defined 
as the composite of cardiovascular death, nonfatal MI, or nonfatal 
stroke). A prespecified, key secondary expanded composite outcome 
included coronary revascularization, hospitalization for unstable 
angina, or heart failure in addition to MACE. Furthermore, prespecified 
secondary end points were time to first event of the individual 
components of the expanded composite outcomes and all-cause death. We 
also examined renal and metabolic outcomes in these 3 risk groups (see 
‘Detailed description of renal and metabolic outcomes and statistical 
considerations’, page 1 in the <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.034516">online-only Data Supplement</a>).</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 cardiovascular and renal outcomes were adjudicated by an independent 
event adjudication committee of experts blinded to the randomization.<sup><a data-tab="pane-pcw-references" href="#R8" id="R8R" class="tab-link">8</a></sup>
 Furthermore, the event adjudication committee assessed whether 
MI/stroke was fatal or nonfatal, through which fatal events were linked 
to subsequent cardiovascular death. Serious and nonserious medical 
adverse events of special interest were reported by the investigator.</p>
<div id="acd3e655" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e655">Statistical Analysis</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 time from randomization to the first occurrence of the outcome was 
analyzed with a Cox proportional hazards model on all randomized 
subjects. The hazard ratios (HRs) and <i>P</i> values between risk 
groups were estimated with multivariable adjustment for prespecified 
baseline factors (sex, region, baseline age, diabetes duration, baseline
 antidiabetic medication, smoking history [never/prior/current], and 
estimated glomerular filtration rate at screening)<sup><a data-tab="pane-pcw-references" href="#R8" id="R8R" class="tab-link">8</a></sup>
 and for treatment allocation (liraglutide versus placebo). The 
treatment effect of liraglutide versus placebo within risk groups was 
estimated with a Cox proportional hazards regression model, with 
treatment, risk group, and the interaction of both as factors, and 
adjusted for the above prespecified baseline factors.<sup><a data-tab="pane-pcw-references" href="#R8" id="R8R" class="tab-link">8</a></sup>
 Furthermore, Kaplan-Meier curves were used to examine the association 
between treatment groups within risk groups and the outcome of interest.
 An interaction value of <i>P</i>&lt;0.05 indicated a significant 
difference in the treatment HRs across the 3 risk groups. No adjustment 
for multiple testing was performed. All patients who underwent 
randomization were included in the analyses and followed up from the 
time of randomization until death or the end of follow-up. To evaluate 
any potential treatment interaction with prior cardiovascular disease, 
sensitivity analyses were conducted that were stratified by 
investigator-reported history of MI/stroke alone or including 
percutaneous coronary intervention or CABG or by carotid stenosis in 
addition to history of MI/stroke. Sensitivity analyses in relation to 
treatment differences were performed, with adjustment for all-cause 
death as a competing risk using the Fine and Gray regression method.<sup><a data-tab="pane-pcw-references" href="#R8" id="R8R" class="tab-link">8</a>,<a data-tab="pane-pcw-references" href="#R11" id="R11R" class="tab-link">11</a></sup> The number needed to treat was calculated from the predicted survival rates at 3 years after randomization.<sup><a data-tab="pane-pcw-references" href="#R12" id="R12R" class="tab-link">12</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Serious and nonserious medical adverse events of special interest between the 3 treatment groups were summarized.</p>
<div id="acd3e693" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e693">Results</h3>
<div id="acd3e698" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e698">Baseline Characteristics</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Of
 the 9340 patients, 3692 (39.5%) had a history of MI/stroke, 3083 
(33.0%) had evidence of atherosclerotic cardiovascular disease without 
an MI/stroke, and 2565 (27.5%) had cardiovascular risk factors alone. 
The baseline demographics and cardiovascular histories of these 3 groups
 are detailed in <a class="ref showTableEvent" data-id="T1" href="#T1">Tables 1</a> and <a class="ref showTableEvent" data-id="T2" href="#T2">2</a>,
 respectively. Patients with a history of MI/stroke had a higher 
frequency of cardiovascular risk factors. Of patients with a history of 
MI/stroke, 76.0% had a history of MI, and 28.1% had a previous ischemic 
stroke; revascularization with percutaneous coronary intervention had 
been performed in 43.3%, and 24.5% had a history of CABG compared with 
31.4% and 20.3%, respectively, in patients with atherosclerotic 
cardiovascular disease without an MI/stroke. More patients with a 
history of MI/stroke had evidence of left ventricular systolic 
dysfunction and heart failure. Median follow-up was 3.8 years.</p>
<div id="T1" class="anchor-spacer"></div>
<div class="article-table-content" id="T1">
<table class="table article-section__table">
<caption><strong><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns"><strong class="captionLabel">Table 1.</strong> Baseline Demographics and Characteristics by History of Myocardial Infarction and/or Stroke and Cardiovascular Disease</p></strong></caption>
<thead xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">
<tr>
<th colspan="1" rowspan="3" align="left"></th>
<th colspan="3" rowspan="1" align="center">Overall</th>
<th colspan="6" rowspan="1" align="center"></th>
</tr>
<tr>
<th colspan="1" rowspan="2" align="center">With Prior MI/Stroke (n=3692)</th>
<th colspan="1" rowspan="2" align="center">CVD Without MI or Stroke (n=3083)</th>
<th colspan="1" rowspan="2" align="center">Cardiovascular Risk Factors Alone (n=2565)</th>
<th colspan="2" rowspan="1" align="center">With Prior MI/Stroke (n=3692)</th>
<th colspan="2" rowspan="1" align="center">CVD Without MI or Stroke (n=3083)</th>
<th colspan="2" rowspan="1" align="center">Cardiovascular Risk Factors Alone (n=2565)</th>
</tr>
<tr>
<th colspan="1" rowspan="1" align="center">Placebo (n=1827)</th>
<th colspan="1" rowspan="1" align="center">Liraglutide (n=1865)</th>
<th colspan="1" rowspan="1" align="center">Placebo (n=1545)</th>
<th colspan="1" rowspan="1" align="center">Liraglutide (n=1538)</th>
<th colspan="1" rowspan="1" align="center">Placebo (n=1300)</th>
<th colspan="1" rowspan="1" align="center">Liraglutide (n=1265)</th>
</tr>
</thead>
<tbody xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">
<tr>
<td colspan="1" rowspan="1" align="left">Male, n (%)</td>
<td colspan="1" rowspan="1" align="center">2693 (72.9)</td>
<td colspan="1" rowspan="1" align="center">1922 (62.3)</td>
<td colspan="1" rowspan="1" align="center">1388 (54.1)</td>
<td colspan="1" rowspan="1" align="center">1333 (73.0)</td>
<td colspan="1" rowspan="1" align="center">1360 (72.9)</td>
<td colspan="1" rowspan="1" align="center">952 (61.6)</td>
<td colspan="1" rowspan="1" align="center">970 (63.1)</td>
<td colspan="1" rowspan="1" align="center">707 (54.4)</td>
<td colspan="1" rowspan="1" align="center">681 (53.8)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Age (SD), y</td>
<td colspan="1" rowspan="1" align="center">63.4 (7.5)</td>
<td colspan="1" rowspan="1" align="center">64.3 (7.4)</td>
<td colspan="1" rowspan="1" align="center">65.5 (6.4)</td>
<td colspan="1" rowspan="1" align="center">63.6 (7.5)</td>
<td colspan="1" rowspan="1" align="center">63.3 (7.5)</td>
<td colspan="1" rowspan="1" align="center">64.4 (7.5)</td>
<td colspan="1" rowspan="1" align="center">64.2 (7.3)</td>
<td colspan="1" rowspan="1" align="center">65.5 (6.3)</td>
<td colspan="1" rowspan="1" align="center">65.5 (6.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">BMI (SD), kg/m<sup>2</sup>
</td>
<td colspan="1" rowspan="1" align="center">32.0 (5.9)</td>
<td colspan="1" rowspan="1" align="center">32.4 (6.1)</td>
<td colspan="1" rowspan="1" align="center">33.4 (6.9)</td>
<td colspan="1" rowspan="1" align="center">31.9 (6.0)</td>
<td colspan="1" rowspan="1" align="center">32.0 (5.9)</td>
<td colspan="1" rowspan="1" align="center">32.4 (6.2)</td>
<td colspan="1" rowspan="1" align="center">32.4 (6.1)</td>
<td colspan="1" rowspan="1" align="center">33.3 (6.7)</td>
<td colspan="1" rowspan="1" align="center">33.4 (7.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Diabetes mellitus duration (SD), y</td>
<td colspan="1" rowspan="1" align="center">12.6 (8.1)</td>
<td colspan="1" rowspan="1" align="center">13.0 (8.0)</td>
<td colspan="1" rowspan="1" align="center">12.9 (7.9)</td>
<td colspan="1" rowspan="1" align="center">12.7 (8.2)</td>
<td colspan="1" rowspan="1" align="center">12.4 (8.0)</td>
<td colspan="1" rowspan="1" align="center">13.2 (8.1)</td>
<td colspan="1" rowspan="1" align="center">12.9 (7.8)</td>
<td colspan="1" rowspan="1" align="center">13.2 (8.0)</td>
<td colspan="1" rowspan="1" align="center">12.7 (7.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">HbA<sub>1c</sub> (SD), %</td>
<td colspan="1" rowspan="1" align="center">8.7 (1.5)</td>
<td colspan="1" rowspan="1" align="center">8.6 (1.5)</td>
<td colspan="1" rowspan="1" align="center">8.8 (1.6)</td>
<td colspan="1" rowspan="1" align="center">8.7 (1.5)</td>
<td colspan="1" rowspan="1" align="center">8.8 (1.6)</td>
<td colspan="1" rowspan="1" align="center">8.6 (1.5)</td>
<td colspan="1" rowspan="1" align="center">8.6 (1.5)</td>
<td colspan="1" rowspan="1" align="center">8.7 (1.5)</td>
<td colspan="1" rowspan="1" align="center">8.8 (1.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">HbA<sub>1c</sub> (SD), mmol/mol</td>
<td colspan="1" rowspan="1" align="center">71.9 (16.8)</td>
<td colspan="1" rowspan="1" align="center">70.4 (16.1)</td>
<td colspan="1" rowspan="1" align="center">72.2 (17.2)</td>
<td colspan="1" rowspan="1" align="center">71.5 (16.4)</td>
<td colspan="1" rowspan="1" align="center">72.4 (17.1)</td>
<td colspan="1" rowspan="1" align="center">70.3 (15.9)</td>
<td colspan="1" rowspan="1" align="center">70.6 (16.3)</td>
<td colspan="1" rowspan="1" align="center">71.7 (16.6)</td>
<td colspan="1" rowspan="1" align="center">72.8 (17.7)</td>
</tr>
<tr><td colspan="10" rowspan="1" align="left">Smoking status, n (%)</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Current smoker</td>
<td colspan="1" rowspan="1" align="center">516 (14.0)</td>
<td colspan="1" rowspan="1" align="center">343 (11.1)</td>
<td colspan="1" rowspan="1" align="center">271 (10.6)</td>
<td colspan="1" rowspan="1" align="center">254 (13.9)</td>
<td colspan="1" rowspan="1" align="center">262 (14.0)</td>
<td colspan="1" rowspan="1" align="center">167 (10.8)</td>
<td colspan="1" rowspan="1" align="center">176 (11.4)</td>
<td colspan="1" rowspan="1" align="center">142 (10.9)</td>
<td colspan="1" rowspan="1" align="center">129 (10.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Never smoker</td>
<td colspan="1" rowspan="1" align="center">1251 (33.9)</td>
<td colspan="1" rowspan="1" align="center">1345 (43.6)</td>
<td colspan="1" rowspan="1" align="center">1274 (49.7)</td>
<td colspan="1" rowspan="1" align="center">624 (34.2)</td>
<td colspan="1" rowspan="1" align="center">627 (33.6)</td>
<td colspan="1" rowspan="1" align="center">660 (42.7)</td>
<td colspan="1" rowspan="1" align="center">685 (44.5)</td>
<td colspan="1" rowspan="1" align="center">636 (48.9)</td>
<td colspan="1" rowspan="1" align="center">638 (50.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Previous smoker</td>
<td colspan="1" rowspan="1" align="center">1925 (52.1)</td>
<td colspan="1" rowspan="1" align="center">1395 (45.2)</td>
<td colspan="1" rowspan="1" align="center">1020 (39.8)</td>
<td colspan="1" rowspan="1" align="center">949 (51.9)</td>
<td colspan="1" rowspan="1" align="center">976 (52.3)</td>
<td colspan="1" rowspan="1" align="center">718 (46.5)</td>
<td colspan="1" rowspan="1" align="center">677 (44.0)</td>
<td colspan="1" rowspan="1" align="center">522 (40.2)</td>
<td colspan="1" rowspan="1" align="center">498 (39.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">SBP (SD), mm Hg</td>
<td colspan="1" rowspan="1" align="center">134.7 (17.7)</td>
<td colspan="1" rowspan="1" align="center">135.9 (17.6)</td>
<td colspan="1" rowspan="1" align="center">137.5 (17.8)</td>
<td colspan="1" rowspan="1" align="center">134.8 (17.8)</td>
<td colspan="1" rowspan="1" align="center">134.7 (17.7)</td>
<td colspan="1" rowspan="1" align="center">136.2 (17.6)</td>
<td colspan="1" rowspan="1" align="center">135.7 (17.6)</td>
<td colspan="1" rowspan="1" align="center">137.1 (17.7)</td>
<td colspan="1" rowspan="1" align="center">137.9 (17.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">DBP (SD), mm Hg</td>
<td colspan="1" rowspan="1" align="center">77.0 (10.2)</td>
<td colspan="1" rowspan="1" align="center">76.7 (10.2)</td>
<td colspan="1" rowspan="1" align="center">77.7 (10.3)</td>
<td colspan="1" rowspan="1" align="center">76.8 (10.2)</td>
<td colspan="1" rowspan="1" align="center">77.2 (10.2</td>
<td colspan="1" rowspan="1" align="center">76.6 (10.0)</td>
<td colspan="1" rowspan="1" align="center">76.9 (10.4)</td>
<td colspan="1" rowspan="1" align="center">77.7 (10.2)</td>
<td colspan="1" rowspan="1" align="center">77.6 (10.5)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Heart rate (SD), bpm</td>
<td colspan="1" rowspan="1" align="center">71.9 (11.4)</td>
<td colspan="1" rowspan="1" align="center">72.3 (11.2)</td>
<td colspan="1" rowspan="1" align="center">74.0 (11.4)</td>
<td colspan="1" rowspan="1" align="center">71.6 (11.7)</td>
<td colspan="1" rowspan="1" align="center">72.1 (11.2)</td>
<td colspan="1" rowspan="1" align="center">72.4 (11.3)</td>
<td colspan="1" rowspan="1" align="center">72.2 (11.1)</td>
<td colspan="1" rowspan="1" align="center">74.0 (11.1)</td>
<td colspan="1" rowspan="1" align="center">74.1 (11.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">eGFR from the MDRD equation (SD), mL·min<sup>−1</sup>·1.73 m<sup>−2</sup>
</td>
<td colspan="1" rowspan="1" align="center">81.5 (27.6)</td>
<td colspan="1" rowspan="1" align="center">82.3 (26.4)</td>
<td colspan="1" rowspan="1" align="center">76.4 (27.8)</td>
<td colspan="1" rowspan="1" align="center">81.5 (27.8)</td>
<td colspan="1" rowspan="1" align="center">81.6 (27.4)</td>
<td colspan="1" rowspan="1" align="center">82.6 (26.0)</td>
<td colspan="1" rowspan="1" align="center">81.9 (26.8)</td>
<td colspan="1" rowspan="1" align="center">76.9 (27.3)</td>
<td colspan="1" rowspan="1" align="center">76.0 (28.2)</td>
</tr>
<tr><td colspan="10" rowspan="1" align="left">Renal function</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Severe (&lt;30 mL·min<sup>−1</sup>·1.73 m<sup>−2</sup>), n (%)</td>
<td colspan="1" rowspan="1" align="center">76 (2.1)</td>
<td colspan="1" rowspan="1" align="center">41 (1.3)</td>
<td colspan="1" rowspan="1" align="center">107 (4.2)</td>
<td colspan="1" rowspan="1" align="center">34 (1.9)</td>
<td colspan="1" rowspan="1" align="center">42 (2.3)</td>
<td colspan="1" rowspan="1" align="center">17 (1.1)</td>
<td colspan="1" rowspan="1" align="center">24 (1.6)</td>
<td colspan="1" rowspan="1" align="center">56 (4.3)</td>
<td colspan="1" rowspan="1" align="center">51 (4.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Moderate (30–59 mL·min<sup>−1</sup>·1.73 m<sup>−2</sup>), n (%)</td>
<td colspan="1" rowspan="1" align="center">727 (19.7)</td>
<td colspan="1" rowspan="1" align="center">567 (18.4)</td>
<td colspan="1" rowspan="1" align="center">640 (25.0)</td>
<td colspan="1" rowspan="1" align="center">353 (19.3)</td>
<td colspan="1" rowspan="1" align="center">374 (20.1)</td>
<td colspan="1" rowspan="1" align="center">279 (18.1)</td>
<td colspan="1" rowspan="1" align="center">288 (18.7)</td>
<td colspan="1" rowspan="1" align="center">303 (23.3)</td>
<td colspan="1" rowspan="1" align="center">337 (26.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Mild (60–89 mL·min<sup>−1</sup>·1.73 m<sup>−2</sup>), n (%)</td>
<td colspan="1" rowspan="1" align="center">1549 (42.0)</td>
<td colspan="1" rowspan="1" align="center">1322 (42.9)</td>
<td colspan="1" rowspan="1" align="center">1036 (40.4)</td>
<td colspan="1" rowspan="1" align="center">777 (42.5)</td>
<td colspan="1" rowspan="1" align="center">772 (41.4)</td>
<td colspan="1" rowspan="1" align="center">651 (42.1)</td>
<td colspan="1" rowspan="1" align="center">671 (43.6)</td>
<td colspan="1" rowspan="1" align="center">547 (42.1)</td>
<td colspan="1" rowspan="1" align="center">489 (38.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Normal (≥90 mL·min<sup>−1</sup>·1.73 m<sup>−2</sup>), n (%)</td>
<td colspan="1" rowspan="1" align="center">1340 (36.3)</td>
<td colspan="1" rowspan="1" align="center">1153 (37.4)</td>
<td colspan="1" rowspan="1" align="center">782 (30.5)</td>
<td colspan="1" rowspan="1" align="center">663 (36.3)</td>
<td colspan="1" rowspan="1" align="center">677 (36.3)</td>
<td colspan="1" rowspan="1" align="center">598 (38.7)</td>
<td colspan="1" rowspan="1" align="center">555 (36.1)</td>
<td colspan="1" rowspan="1" align="center">394 (30.3)</td>
<td colspan="1" rowspan="1" align="center">388 (30.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Total cholesterol (SD), mg/dL</td>
<td colspan="1" rowspan="1" align="center">165.1 (43.6)</td>
<td colspan="1" rowspan="1" align="center">169.9 (46.5)</td>
<td colspan="1" rowspan="1" align="center">177.8 (45.0)</td>
<td colspan="1" rowspan="1" align="center">166.0 (44.5)</td>
<td colspan="1" rowspan="1" align="center">164.3 (42.6)</td>
<td colspan="1" rowspan="1" align="center">169.3 (47.1)</td>
<td colspan="1" rowspan="1" align="center">170.4 (45.9)</td>
<td colspan="1" rowspan="1" align="center">176.7 (43.7)</td>
<td colspan="1" rowspan="1" align="center">178.9 (46.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">LDL cholesterol (SD), mg/dL</td>
<td colspan="1" rowspan="1" align="center">86.9 (35.7)</td>
<td colspan="1" rowspan="1" align="center">89.6 (36.7)</td>
<td colspan="1" rowspan="1" align="center">95.0 (36.1)</td>
<td colspan="1" rowspan="1" align="center">87.6 (35.9)</td>
<td colspan="1" rowspan="1" align="center">86.2 (35.4)</td>
<td colspan="1" rowspan="1" align="center">89.0 (35.9)</td>
<td colspan="1" rowspan="1" align="center">90.1 (37.5)</td>
<td colspan="1" rowspan="1" align="center">94.7 (36.0)</td>
<td colspan="1" rowspan="1" align="center">95.4 (36.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">HDL cholesterol (SD), mg/dL</td>
<td colspan="1" rowspan="1" align="center">43.6 (11.6)</td>
<td colspan="1" rowspan="1" align="center">45.6 (12.3)</td>
<td colspan="1" rowspan="1" align="center">47.7 (12.9)</td>
<td colspan="1" rowspan="1" align="center">43.8 (11.4)</td>
<td colspan="1" rowspan="1" align="center">43.5 (11.7)</td>
<td colspan="1" rowspan="1" align="center">45.6 (12.5)</td>
<td colspan="1" rowspan="1" align="center">45.6 (12.1)</td>
<td colspan="1" rowspan="1" align="center">47.6 (12.7)</td>
<td colspan="1" rowspan="1" align="center">47.8 (13.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Triglycerides (SD), mg/dL</td>
<td colspan="1" rowspan="1" align="center">183.2 (133.3)</td>
<td colspan="1" rowspan="1" align="center">183.2 (150.3)</td>
<td colspan="1" rowspan="1" align="center">183.9 (140.5)</td>
<td colspan="1" rowspan="1" align="center">183.7 (143.0)</td>
<td colspan="1" rowspan="1" align="center">182.8 (123.0)</td>
<td colspan="1" rowspan="1" align="center">183.3 (171.2)</td>
<td colspan="1" rowspan="1" align="center">183.1 (126.0)</td>
<td colspan="1" rowspan="1" align="center">180.3 (141.2)</td>
<td colspan="1" rowspan="1" align="center">187.5 (139.8)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Antihypertensive therapy, n (%)</td>
<td colspan="1" rowspan="1" align="center">3473 (94.1)</td>
<td colspan="1" rowspan="1" align="center">2854 (92.6)</td>
<td colspan="1" rowspan="1" align="center">2304 (89.8)</td>
<td colspan="1" rowspan="1" align="center">1712 (93.7)</td>
<td colspan="1" rowspan="1" align="center">1761 (94.4)</td>
<td colspan="1" rowspan="1" align="center">1421 (92.0)</td>
<td colspan="1" rowspan="1" align="center">1433 (93.2)</td>
<td colspan="1" rowspan="1" align="center">1169 (89.9)</td>
<td colspan="1" rowspan="1" align="center">1135 (89.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Diuretics, n (%)</td>
<td colspan="1" rowspan="1" align="center">1533 (41.5)</td>
<td colspan="1" rowspan="1" align="center">1207 (39.2)</td>
<td colspan="1" rowspan="1" align="center">1166 (45.5)</td>
<td colspan="1" rowspan="1" align="center">767 (42.0)</td>
<td colspan="1" rowspan="1" align="center">766 (41.1)</td>
<td colspan="1" rowspan="1" align="center">619 (40.1)</td>
<td colspan="1" rowspan="1" align="center">588 (38.2)</td>
<td colspan="1" rowspan="1" align="center">567 (43.6)</td>
<td colspan="1" rowspan="1" align="center">599 (47.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Lipid-lowering drugs, n (%)</td>
<td colspan="1" rowspan="1" align="center">3073 (83.2)</td>
<td colspan="1" rowspan="1" align="center">2364 (76.7)</td>
<td colspan="1" rowspan="1" align="center">1642 (64.0)</td>
<td colspan="1" rowspan="1" align="center">1500 (82.1)</td>
<td colspan="1" rowspan="1" align="center">1573 (84.3)</td>
<td colspan="1" rowspan="1" align="center">1173 (75.9)</td>
<td colspan="1" rowspan="1" align="center">1191 (77.4)</td>
<td colspan="1" rowspan="1" align="center">842 (64.8)</td>
<td colspan="1" rowspan="1" align="center">800 (63.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Platelet aggregation inhibitors, n (%)</td>
<td colspan="1" rowspan="1" align="center">2937 (79.6)</td>
<td colspan="1" rowspan="1" align="center">2252 (73.0)</td>
<td colspan="1" rowspan="1" align="center">1137 (44.3)</td>
<td colspan="1" rowspan="1" align="center">1450 (79.4)</td>
<td colspan="1" rowspan="1" align="center">1487 (79.7)</td>
<td colspan="1" rowspan="1" align="center">1108 (71.7)</td>
<td colspan="1" rowspan="1" align="center">1144 (74.4)</td>
<td colspan="1" rowspan="1" align="center">563 (43.3)</td>
<td colspan="1" rowspan="1" align="center">574 (45.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Antithrombotic medications, n (%)</td>
<td colspan="1" rowspan="1" align="center">300 (8.1)</td>
<td colspan="1" rowspan="1" align="center">160 (5.2)</td>
<td colspan="1" rowspan="1" align="center">163 (6.4)</td>
<td colspan="1" rowspan="1" align="center">151 (8.3)</td>
<td colspan="1" rowspan="1" align="center">149 (8.0)</td>
<td colspan="1" rowspan="1" align="center">80 (5.2)</td>
<td colspan="1" rowspan="1" align="center">80 (5.2)</td>
<td colspan="1" rowspan="1" align="center">83 (6.4)</td>
<td colspan="1" rowspan="1" align="center">80 (6.3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Blood glucose-lowering drugs, excluding insulin, n (%)</td>
<td colspan="1" rowspan="1" align="center">3234 (87.6)</td>
<td colspan="1" rowspan="1" align="center">2755 (89.4)</td>
<td colspan="1" rowspan="1" align="center">2253 (87.8)</td>
<td colspan="1" rowspan="1" align="center">1605 (87.8)</td>
<td colspan="1" rowspan="1" align="center">1629 (87.3)</td>
<td colspan="1" rowspan="1" align="center">1385 (89.6)</td>
<td colspan="1" rowspan="1" align="center">1370 (89.1)</td>
<td colspan="1" rowspan="1" align="center">1139 (87.6)</td>
<td colspan="1" rowspan="1" align="center">1114 (88.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Insulin treatment, n (%)</td>
<td colspan="1" rowspan="1" align="center">1697 (46.0)</td>
<td colspan="1" rowspan="1" align="center">1338 (43.4)</td>
<td colspan="1" rowspan="1" align="center">1134 (44.2)</td>
<td colspan="1" rowspan="1" align="center">851 (46.6)</td>
<td colspan="1" rowspan="1" align="center">846 (45.4)</td>
<td colspan="1" rowspan="1" align="center">697 (45.1)</td>
<td colspan="1" rowspan="1" align="center">641 (41.7)</td>
<td colspan="1" rowspan="1" align="center">583 (44.8)</td>
<td colspan="1" rowspan="1" align="center">551 (43.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Insulin-naive, n (%)</td>
<td colspan="1" rowspan="1" align="center">1995 (54.0)</td>
<td colspan="1" rowspan="1" align="center">1745 (56.6)</td>
<td colspan="1" rowspan="1" align="center">1431 (55.8)</td>
<td colspan="1" rowspan="1" align="center">976 (53.4)</td>
<td colspan="1" rowspan="1" align="center">1019 (54.6)</td>
<td colspan="1" rowspan="1" align="center">848 (54.9)</td>
<td colspan="1" rowspan="1" align="center">897 (58.3)</td>
<td colspan="1" rowspan="1" align="center">717 (55.2)</td>
<td colspan="1" rowspan="1" align="center">714 (56.4)</td>
</tr>
</tbody>
</table>
<div class="tableFooter"><div xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="footnote"><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">BMI
 indicates body mass index; CVD, cardiovascular disease; DBP, diastolic 
blood pressure; eGFR, estimated glomerular filtration rate; HbA<sub>1c</sub>,
 glycohemoglobin; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; MDRD, Modified Diet in Renal Disease; MI, myocardial 
infarction; SBP, systolic blood pressure; and SD, standard deviation.</p></div></div>
</div>
<div id="acd3e1833" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e1833">Risk of Cardiovascular Events and Mortality According to Risk Groups Regardless of Treatment</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Patients
 with a history of MI/stroke had the highest risk of MACE (694 events of
 3692 [18.8%]), followed by patients with established atherosclerotic 
cardiovascular disease without a history of MI/stroke (357 of 3083 
[11.6%]) and patients with cardiovascular risk factors alone (251 of 
2565 [9.8%]). The adjusted HRs for MACE were 2.13 (95% CI, 1.84–2.47; <i>P</i>&lt;0.0001) and 1.29 (95% CI, 1.10–1.52; <i>P</i>=0.0021)
 in patients with a history of MI/stroke and those with established 
atherosclerotic cardiovascular disease without MI/stroke, respectively, 
compared with patients with cardiovascular risk factors alone. Incidence
 rates of MACE were 5.0 per 100 person-years of observation (PYO) in 
patients with a history of MI/stroke, 3.0 per 100 PYO in patients with 
established atherosclerotic cardiovascular disease without MI/stroke, 
and 2.6 per 100 PYO in those with cardiovascular risk factors alone.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Similar
 results were obtained for expanded MACE when patients with MI/stroke 
(1052 of 3692 [28.5%]; HR, 2.27; 95% CI, 2.01–2.57; <i>P</i>&lt;0.0001) 
and with established atherosclerotic cardiovascular disease without 
MI/stroke (597 of 3083 [19.4%]; HR, 1.52; 95% CI, 1.34–1.74; <i>P</i>&lt;0.0001)
 were compared with those with cardiovascular risk factors alone (361 of
 2565 [14.1%]). Incidence rates of expanded MACE were 7.5 per 100 PYO in
 patients with a history of MI/stroke, 5.1 per 100 PYO in patients with 
established atherosclerotic cardiovascular disease without MI/stroke, 
and 3.7 per 100 PYO in those with cardiovascular risk factors alone.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Incidence
 rates for time to the first of the individual components of the primary
 and secondary outcomes in the 3 groups (history of MI/stroke versus 
established atherosclerotic cardiovascular disease without MI/stroke 
versus cardiovascular risk factors alone) were as follows: 
cardiovascular death (1.9 versus 1.1 versus 1.1 per 100 PYO), nonfatal 
MI (2.3 versus 1.5 versus 1.0 per 100 PYO), nonfatal stroke (1.3 versus 
0.8 versus 0.7 per 100 PYO), coronary revascularization (3.3 versus 2.4 
versus 1.0 per 100 PYO), hospitalization for unstable angina (1.0 versus
 0.7 versus 0.2 per 100 PYO), and hospitalization for heart failure (1.7
 versus 1.1 versus 1.0 per 100 PYO). All-cause death was also higher in 
patients with history of MI/stroke compared with patients with 
established atherosclerotic cardiovascular disease without MI/stroke or 
those with cardiovascular risk factors alone (incidence rates, 2.9 
versus 1.9 versus 2.0 per 100 PYO, respectively).</p>
<div id="acd3e1860" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e1860">Effects of Liraglutide on Cardiovascular Events and Mortality in Patients With a History of MI and/or Stroke</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 primary composite end point occurred in 322 of 1865 patients (17.3%) 
with an incidence rate of 4.6 per 100 PYO in the liraglutide group 
compared with 372 of the 1827 patients (20.4%) with an incidence rate of
 5.4 per 100 PYO in the placebo group (HR, 0.85; 95% CI, 0.73–0.99). 
Time to the first of the individual components of the 3-point MACE was 
consistently numerically reduced with liraglutide, including 
cardiovascular death (HR, 0.80; 95% CI, 0.63–1.02), nonfatal MI (HR, 
0.83; 95% CI, 0.67–1.03), and nonfatal stroke (HR, 0.95; 95% CI, 
0.71–1.27; <a data-tab="pane-pcw-Figures" href="#F1" id="F1R" class="">Figures 1</a> and <a data-tab="pane-pcw-Figures" href="#F2" id="F2R" class="">2</a>). All-cause death was numerically reduced by 10% (HR, 0.90; 95% CI, 0.74–1.09; <a data-tab="pane-pcw-Figures" href="#F2" id="F2R" class="">Figure 2</a>).
 Liraglutide treatment significantly reduced the key secondary expanded 
end point (7.1 events per 100 PYO) compared with the placebo group (8.0 
events per PYO; HR, 0.88; 95% CI, 0.78–0.99; <a data-tab="pane-pcw-Figures" href="#F2" id="F2R" class="">Figure 2</a>).</p>
<figure id="F1" class="article__inlineFigure"><img class="figure__image" src="2884fig01.gif" alt="Figure 1."><div class="figure-links"><ul class="rlist--inline">
<li><a href="https://www.ahajournals.org/cms/attachment/c1e656ac-20ee-47f7-85f2-0ab546a05b28/2884fig01.gif" download="">Download figure</a></li>
<li><a href="https://www.ahajournals.org/action/downloadFigures?id=F1&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516" class="ppt-figure-link">Download PowerPoint</a></li>
</ul></div>
<figcaption><strong class="figure__title"></strong><span class="figure__caption"><p><strong class="captionLabel">Figure 1.</strong> <strong>Occurrence
 of the primary composite outcome (A), cardiovascular (CV) death (B), 
nonfatal myocardial infarction (MI; C), and nonfatal stroke (D), 
stratified by history of MI and/or stroke, established cardiovascular 
disease (CVD) without MI/stroke, or cardiovascular risk factors alone.</strong> Primary composite end point (cardiovascular death, nonfatal MI, or nonfatal stroke) from randomization to follow-up. The <i>x</i>
 axis was truncated at 54 months because &lt;10% of patients remained in
 the trial after this time point. HR indicates hazard ratio between 
treatment groups (liraglutide vs placebo).</p></span></figcaption></figure><figure id="F2" class="article__inlineFigure"><img class="figure__image" src="2884fig02.gif" alt="Figure 2."><div class="figure-links"><ul class="rlist--inline">
<li><a href="https://www.ahajournals.org/cms/attachment/b398e3fd-1c47-4a4f-b66b-988a7b80ca02/2884fig02.gif" download="">Download figure</a></li>
<li><a href="https://www.ahajournals.org/action/downloadFigures?id=F2&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516" class="ppt-figure-link">Download PowerPoint</a></li>
</ul></div>
<figcaption><strong class="figure__title"></strong><span class="figure__caption"><p><strong class="captionLabel">Figure 2.</strong> <strong>Occurrence
 of cardiovascular outcomes stratified by history of myocardial 
infarction (MI)/stroke, established cardiovascular (CV) disease (CVD) 
without MI/stroke, or cardiovascular risk factors alone.</strong> N 
refers to the number of patients with an event (as a proportion of the 
full analysis set). Lira indicates liraglutide; MACE, major adverse 
cardiovascular event; and PYO, person-years of observation. *Including 
fatal and nonfatal events.</p></span></figcaption></figure><div id="acd3e1910" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e1910">Effects
 of Liraglutide on Cardiovascular Events in Patients With a History of 
Established Atherosclerotic Cardiovascular Disease Without MI/Stroke</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 primary composite end point occurred in 158 of the 1538 patients 
(10.3%) with an incidence rate of 2.7 PYO in the liraglutide group 
compared with 199 of the 1545 patients (12.9%) with an incidence rate of
 3.4 per 100 PYO in the placebo group (HR, 0.76; 95% CI, 0.62–0.94). 
Individual components of 3-point MACE were consistently reduced with 
liraglutide, including cardiovascular death (HR, 0.59; 95% CI, 
0.41–0.84), nonfatal MI (HR, 0.91; 95% CI, 0.68–1.22), and nonfatal 
stroke (HR, 0.68; 95% CI, 0.45–1.03; (<a data-tab="pane-pcw-Figures" href="#F1" id="F1R" class="">Figures 1</a> and <a data-tab="pane-pcw-Figures" href="#F2" id="F2R" class="">2</a>). All-cause death was reduced by 34% (HR, 0.66; 95% CI, 0.51–0.86; <a data-tab="pane-pcw-Figures" href="#F2" id="F2R" class="">Figure 2</a> and <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.034516">Figure I in the online-only Data Supplement</a>).
 Liraglutide treatment also showed consistent reduction of the key 
expanded secondary end point (incidence rate, 4.4 per 100 PYO) compared 
with placebo (incidence rate, 5.7 per 100 PYO; HR, 0.74; 95% CI, 
0.63–0.87; <a data-tab="pane-pcw-Figures" href="#F2" id="F2R" class="">Figure 2</a>).</p>
<div id="acd3e1935" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e1935">Effects of Liraglutide on Cardiovascular Events in Patients With Cardiovascular Risk Factors Alone</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">In
 patients with cardiovascular risk factors alone, the primary composite 
end point occurred in 128 of 1265 patients (10.1%) with an incidence 
rate of 2.6 per 100 PYO in the liraglutide group compared with 123 of 
the 1300 patients (9.5%) with an incidence rate of 2.5 per 100 PYO in 
the placebo group (HR, 1.08; 95% CI, 0.84–1.38). The HRs for liraglutide
 versus placebo for time to the first of the individual components of 
the 3-point MACE were as follows: 0.99 (95% CI, 0.67–1.46) for 
cardiovascular death, 1.00 (95% CI, 0.67–1.49) for nonfatal MI, and 1.12
 (95% CI, 0.68–1.82) for nonfatal stroke (<a data-tab="pane-pcw-Figures" href="#F1" id="F1R" class="">Figures 1</a> and <a data-tab="pane-pcw-Figures" href="#F2" id="F2R" class="">2</a>). The HR for all-cause death was 0.95 (95% CI, 0.72–1.27; <a data-tab="pane-pcw-Figures" href="#F2" id="F2R" class="">Figure 2</a>).
 Liraglutide treatment showed a similar trend for the key secondary 
expanded end point (incidence rate, 3.9 per 100 PYO) compared with the 
placebo group (incidence rate, 3.5 per 100 PYO; HR, 1.12; 95% CI, 
0.91–1.38; <a data-tab="pane-pcw-Figures" href="#F2" id="F2R" class="">Figure 2</a>).</p>
<div id="acd3e1956" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e1956">Comparing the Cardiovascular Effects of Liraglutide Across Risk Groups</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">No statistically significant interactions were found across risk groups for the primary end point (<i>P</i><sub>interaction</sub>=0.11), cardiovascular death (<i>P</i><sub>interaction</sub>=0.19), nonfatal MI (<i>P</i><sub>interaction</sub>=0.71), or nonfatal stroke (<i>P</i><sub>interaction</sub>=0.28), indicating no statistical differences across the subgroups in these post hoc analyses (<a data-tab="pane-pcw-Figures" href="#F1" id="F1R" class="">Figures 1</a> and <a data-tab="pane-pcw-Figures" href="#F2" id="F2R" class="">2</a>). The interaction for the expanded key secondary end point was significant (<i>P</i><sub>interaction</sub>=0.01).
 Liraglutide appeared to reduce cardiovascular outcomes consistently in 
patients with history of MI/stroke and in those with evidence of 
established atherosclerotic cardiovascular disease without MI/stroke. 
However, in patients with cardiovascular risk factors alone, liraglutide
 seemed more neutral with respect to the primary and expanded composite 
end point.</p>
<div id="acd3e1997" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e1997">Analyses of Number Needed to Treat</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 number needed to treat to prevent a first MACE with liraglutide 
compared with placebo over 3 years was 39 in patients with a history of 
MI/stroke and 44 in patients with established atherosclerotic 
cardiovascular disease without MI/stroke. The number needed to treat for
 liraglutide to prevent 1 cardiovascular death was 82 and 63 in these 
respective risk groups.</p>
<div id="acd3e2006" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e2006">Sensitivity Analysis</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">In
 separate subanalyses based on the total LEADER population, we 
stratified by history of MI/stroke alone. Liraglutide reduced 
cardiovascular outcomes regardless of baseline history of MI and/or 
stroke for the primary end point (<i>P</i><sub>interaction</sub>=0.56) and for the key secondary expanded composite end point (<i>P</i><sub>interaction</sub>=0.90). Furthermore, the treatment effect of liraglutide on nonfatal MI (<i>P</i><sub>interaction</sub>=0.39) or nonfatal stroke (<i>P</i><sub>interaction</sub>=0.64)
 was also similar in patients with and without a history of MI/stroke. 
Liraglutide reduced rates of cardiovascular mortality similarly in 
patients with and without a history of MI/stroke (<i>P</i><sub>interaction</sub>=0.79; <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.034516">Figure I in the online-only Data Supplement</a>).
 After stratification by known cerebrovascular or coronary artery 
disease, defined as those with a history of CABG, percutaneous coronary 
intervention, or carotid revascularization in addition to MI/stroke, 
results were similar with comparable relative risk reductions for the 
primary and expanded key secondary end points with liraglutide. Greater 
absolute risk reductions were noted in patients with a history of 
MI/stroke and/or coronary/cerebral revascularization procedures. 
Furthermore, for individual components of the expanded composite end 
point, consistency in risk reductions was observed (<a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.034516">Figure II in the online-only Data Supplement</a>).</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Finally,
 sensitivity analyses taking into account all-cause death as a competing
 risk factor showed similar results for the treatment differences (<a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.034516">Figure III in the online-only Data Supplement</a>).</p>
<div id="acd3e2053" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e2053">Efficacy of Liraglutide on Nephropathy Outcomes, Glycohemoglobin, Weight, and Systolic Blood Pressure According to Risk Groups</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 composite renal outcome was consistently reduced in patients with 
MI/stroke (HR, 0.71; 95% CI, 0.54–0.94) and in those with established 
atherosclerotic cardiovascular disease without a history of MI/stroke 
(HR, 0.66; 95% CI, 0.49–0.90) and numerically lower in those with 
cardiovascular risk factors alone (HR, 0.92; 95% CI, 0.71–1.19; <i>P</i><sub>interaction</sub>=0.23).</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Similar
 effects of liraglutide across risk groups were observed within efficacy
 parameters: differences in glycohemoglobin reduction resulting from 
treatment with liraglutide versus placebo from baseline to the 3-year 
visit were −0.40% (95% CI, −0.50 to −0.31) in patients with a history of
 MI/stroke, −0.43% (95% CI, −0.53 to −0.33) in those with established 
atherosclerotic cardiovascular disease without a history of MI/stroke, 
and −0.34% (95% CI, −0.45 to −0.23) in those with cardiovascular risk 
factors alone (<i>P</i><sub>interaction</sub>=0.48). Differences in 
weight reduction resulting from treatment were also consistent in all 
risk groups: −2.23 kg (95% CI, −2.67 to −1.79), −2.16 kg (95% CI, −2.64 
to −1.69), and −2.43 kg (95% CI, −2.95 to −1.91), respectively (<i>P</i><sub>interaction</sub>=0.74). Furthermore, no differences in treatment effects of liraglutide on systolic blood pressure were seen across groups (<i>P</i><sub>interaction</sub>=0.83).</p>
<div id="acd3e2085" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e2085">Adverse Events</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Adverse events are listed in <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.034516">Table I in the online-only Data Supplement</a>.
 Overall, adverse event percentages were 64.9% in patients with a 
history of MI/stroke, 61.1% in those with established atherosclerotic 
cardiovascular disease without MI/stroke, and 57.3% in those with 
cardiovascular risk factors alone. The proportion of patients with any 
adverse events was similar between the liraglutide and placebo groups in
 patients with a history of MI/stroke (65.0% versus 64.8%), in patients 
with established atherosclerotic cardiovascular disease without 
MI/stroke (62.2% versus 60.0%), and in patients with cardiovascular risk
 factors alone (58.6% versus 56.1%). Similar results were obtained for 
severe adverse events and serious adverse events. However, compared with
 patients on placebo, more patients on liraglutide permanently 
discontinued treatment because of adverse events: for patients with a 
history of MI/stroke, 10.8% versus 8.3%; for those with established 
atherosclerotic cardiovascular disease without MI/stroke, 8.3% versus 
6.3; and for those with cardiovascular risk factors alone, 9.3% versus 
7.0%, respectively. The most frequently reported adverse events were 
gastrointestinal symptoms, which are well-known side effects of 
glucagon-like peptide-1 receptor agonists.</p>
<div id="acd3e2098" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e2098">Discussion</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">In
 this post hoc analysis of the LEADER trial including patients with T2DM
 and high cardiovascular risk, we have shown that patients with a 
history of MI/stroke had a nearly 2-fold greater risk of MACE relative 
to those without. In addition, we have demonstrated a consistent level 
of benefit on all cardiovascular end points, including cardiovascular 
death, associated with the use of liraglutide compared with placebo in 
patients with a history of MI/stroke at baseline and in those with 
established cardiovascular disease without MI/stroke. Similar 
observations were made when patients were further stratified by baseline
 history of coronary or cerebral revascularization. In patients with 
cardiovascular risk factors alone, the estimated HRs—although no 
significant interaction between risk groups was found for the primary 
outcome and no correction for multiplicity was performed—may suggest 
that liraglutide had a neutral effect on cardiovascular outcomes. This 
is consistent with previous analyses of the LEADER trial; however, 
subgroups in analyses are overlapping.<sup><a data-tab="pane-pcw-references" href="#R8" id="R8R" class="tab-link">8</a>,<a data-tab="pane-pcw-references" href="#R13" id="R13R" class="tab-link">13</a></sup>
 Taken together, these data indicate that the cardiovascular benefits of
 liraglutide are observed across a clinically relevant continuum of risk
 in T2DM with atherosclerosis or prior ischemic events. The lack of 
apparent cardiovascular benefit in patients with T2DM and cardiovascular
 risk factors alone may suggest either a threshold effect or that a 
longer duration of therapy is required to demonstrate cardiovascular 
efficacy. However, it could also be a random finding resulting from 
multiplicity issues in post hoc analyses. The finding is in line with 
other trials that also showed a greater effect of intervention on 
cardiovascular outcomes for patients at higher cardiovascular risk.<sup><a data-tab="pane-pcw-references" href="#R14%20R15%20R16%20R17%20R18%20R19" id="R14 R15 R16 R17 R18 R19R" class="tab-link">14–19</a></sup>
 The renal composite outcome, glycohemoglobin, weight, and systolic 
blood pressure were reduced with liraglutide treatment independently of 
risk group.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Patients
 recruited into the LEADER trial were categorized as being either &gt;50
 years of age with established cardiovascular or chronic kidney disease 
or &gt;60 years of age with 1 additional cardiovascular risk factor 
(microalbuminuria or proteinuria, hypertension and left ventricular 
hypertrophy, left ventricular systolic or diastolic dysfunction, or an 
ankle-brachial index &lt;0.9). Hence, although this type of enrollment 
strategy was effective in identifying patients with T2DM at high risk of
 developing cardiovascular events during the trial, it was not ideally 
suited to provide practical information to help physicians decide 
whether the benefits of liraglutide may be seen in patients with or 
without a history of atherosclerotic cardiovascular disease treated 
within a duration of time similar to that of the LEADER trial. 
Clinicians often base decisions on risk reduction therapies on the 
presence or absence of prior MI/stroke or other established 
atherosclerotic cardiovascular disease (secondary prevention) or on 
evidence of risk factors alone (primary prevention)<sup><a data-tab="pane-pcw-references" href="#R1" id="R1R" class="tab-link">1</a>,<a data-tab="pane-pcw-references" href="#R9" id="R9R" class="tab-link">9</a></sup>;
 hence, the assessment of cardiovascular effects based on these 
categories is important. When we examine the outcomes on the basis of 
the presence of MI/stroke, there is no heterogeneity with respect to the
 relative benefits of liraglutide on cardiovascular outcomes; however, a
 more neutral result is observed in those with cardiovascular risk 
factors alone. There is, of course, a large overlap between the &gt;60 
years of age enrollment stratum and the subgroup of patients with 
cardiovascular risk factors alone, and the present finding of neutrality
 is in concordance with the previous subgroup analysis of LEADER, in 
which an actual interaction between the 2 recruitment strata was 
detected, suggesting a differential treatment effect of liraglutide in 
these subgroups.<sup><a data-tab="pane-pcw-references" href="#R8" id="R8R" class="tab-link">8</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Recently,
 the EXSCEL trial (Exenatide Study of Cardiovascular Event Lowering) 
reported cardiovascular outcomes with exenatide, an exendin-4–based 
glucagon-like peptide-1 receptor agonist.<sup><a data-tab="pane-pcw-references" href="#R17" id="R17R" class="tab-link">17</a></sup>
 Similar to LEADER, this trial recruited a patient population with T2DM,
 established cardiovascular disease, and multiple risk factors. Although
 the primary outcome and mortality showed directional consistency with 
LEADER, the primary outcome was not significant with respect to 
superiority. In keeping with subgroup analyses in LEADER, the HR for the
 primary outcome was 0.90 (95% CI, 0.82–1.00) in EXSCEL patients with a 
prior cardiovascular event, defined as clinical manifestation of 
coronary artery disease, ischemic cerebrovascular disease, or 
atherosclerotic peripheral artery disease, versus an HR of 0.99 (95% CI,
 0.77–1.28) in those without a history of a cardiovascular event. In 
line with this trend, the subgroup analysis for SUSTAIN-6 (Trial to 
Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in
 Subjects With Type 2 Diabetes) showed an HR of 0.72 (95% CI, 0.55–0.93)
 for patients with established cardiovascular disease and an HR of 1.00 
(95% CI, 0.41–2.46) for those with cardiovascular risk factors alone (<i>P</i><sub>interaction</sub>=0.49).<sup><a data-tab="pane-pcw-references" href="#R20" id="R20R" class="tab-link">20</a></sup>
 For EXSCEL, SUSTAIN-6, and LEADER, the group without established 
cardiovascular disease, as defined by the inclusion criteria, 
contributed a smaller proportion of primary events because of their 
lower absolute risk.<sup><a data-tab="pane-pcw-references" href="#R8" id="R8R" class="tab-link">8</a>,<a data-tab="pane-pcw-references" href="#R18" id="R18R" class="tab-link">18</a>,<a data-tab="pane-pcw-references" href="#R20" id="R20R" class="tab-link">20</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">In
 the CANVAS program (Canagliflozin Cardiovascular Assessment Study), the
 cardiovascular outcomes trial investigating the sodium-glucose 
cotransporter-2 inhibitor canagliflozin,<sup><a data-tab="pane-pcw-references" href="#R21" id="R21R" class="tab-link">21</a></sup>
 patients with T2DM were enrolled who were ≥50 years of age and had ≥2 
cardiovascular risk factors or were ≥30 years of age and with a history 
of cardiovascular event defined as stroke, MI, hospitalization for 
unstable angina, CABG, peripheral revascularization, and carotid or 
peripheral vascular disease or amputation resulting from vascular 
disease. Overall, patients enrolled in the CANVAS program were at a 
lower risk than patients in LEADER. This is manifested by seemingly 
lower event rates in the 2 cardiovascular risk cohorts in CANVAS 
compared with the LEADER population stratified by MI/stroke (for MACE: 
1.6 versus 2.8 per 100 patient-years for the lower-risk groups and 3.7 
versus 5.0 per 100 patient-years for the higher-risk groups, 
respectively). Canagliflozin reduced cardiovascular outcomes primarily 
in patients with prior cardiovascular disease, with a neutral outcome 
for MACE observed in those in the primary prevention subgroup, although 
consistent benefits were seen with respect to heart failure and renal 
end points.<sup><a data-tab="pane-pcw-references" href="#R21" id="R21R" class="tab-link">21</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">There
 are limitations to these analyses of the LEADER data. First, we do not 
have the time from the self-reported pretrial MI/stroke to 
randomization. Because the first year after the event is usually 
considered a higher-risk period for recurrent events,<sup><a data-tab="pane-pcw-references" href="#R5" id="R5R" class="tab-link">5</a></sup>
 efficacy of liraglutide in this cohort would have been interesting to 
evaluate. Second, there was a lack of detail in the collection of 
information of history of cardiovascular disease before enrollment; for 
example, baseline assessments of cardiovascular disease were lacking. In
 addition, because of the lower number of patients within the subgroups 
of interest compared with the overall trial population, there is limited
 statistical power to determine the effects of liraglutide within these 
subgroups.</p>
<div id="acd3e2175" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e2175">Conclusions</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">In
 this clinically relevant post hoc analysis of the LEADER trial, we 
demonstrate similar relative risk reductions yet higher absolute risk 
reductions of liraglutide on cardiovascular events in patients with a 
history of MI/stroke. Liraglutide exerts a consistent benefit in 
patients with established atherosclerotic cardiovascular disease with 
and without a history of MI/stroke; however, it appears to be neutral in
 patients with cardiovascular risk factors alone. The reason for no 
apparent cardiovascular benefit in patients with cardiovascular risk 
factors alone could be that the baseline risk was lower, and 
establishing any potential effect might require a longer treatment 
period or larger sample size. Nevertheless, all patients with T2DM 
regardless of risk group benefit from liraglutide treatment in regard to
 reduced renal outcomes, improved glycemic control, weight reduction, 
and better blood pressure control. These data may provide clinicians 
with important information to help identify appropriate patients who 
would most benefit from liraglutide therapy in their practice.</p>
<div id="T2" class="anchor-spacer"></div>
<div class="article-table-content" id="T2">
<table class="table article-section__table">
<caption><strong><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns"><strong class="captionLabel">Table 2.</strong>
 Cardiovascular History and Complications at Screening by a History of 
Myocardial Infarction and/or Stroke and Cardiovascular Disease</p></strong></caption>
<thead xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">
<tr>
<th colspan="1" rowspan="3" align="left"></th>
<th colspan="3" rowspan="1" align="center">Overall, n (%)</th>
<th colspan="6" rowspan="1" align="center"></th>
</tr>
<tr>
<th colspan="1" rowspan="2" align="center">With Prior MI/Stroke (n=3692)</th>
<th colspan="1" rowspan="2" align="center">CVD Without MI or Stroke (n=3083)</th>
<th colspan="1" rowspan="2" align="center">Cardiovascular Risk Factors Alone (n=2565)</th>
<th colspan="2" rowspan="1" align="center">With Prior MI/Stroke (n=3692), n (%)</th>
<th colspan="2" rowspan="1" align="center">CVD Without MI or Stroke (n=3083), n (%)</th>
<th colspan="2" rowspan="1" align="center">Cardiovascular Risk Factors Alone (n=2565), n (%)</th>
</tr>
<tr>
<th colspan="1" rowspan="1" align="center">Placebo (n=1827)</th>
<th colspan="1" rowspan="1" align="center">Liraglutide (n=1865)</th>
<th colspan="1" rowspan="1" align="center">Placebo (n=1545)</th>
<th colspan="1" rowspan="1" align="center">Liraglutide (n=1538)</th>
<th colspan="1" rowspan="1" align="center">Placebo (n=1300)</th>
<th colspan="1" rowspan="1" align="center">Liraglutide (n=1265)</th>
</tr>
</thead>
<tbody xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">
<tr>
<td colspan="1" rowspan="1" align="left">Myocardial infarction</td>
<td colspan="1" rowspan="1" align="center">2807 (76.0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">1373 (75.2)</td>
<td colspan="1" rowspan="1" align="center">1434 (76.9)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Arrhythmia</td>
<td colspan="1" rowspan="1" align="center">643 (17.4)</td>
<td colspan="1" rowspan="1" align="center">494 (16.0)</td>
<td colspan="1" rowspan="1" align="center">302 (11.8)</td>
<td colspan="1" rowspan="1" align="center">314 (17.2)</td>
<td colspan="1" rowspan="1" align="center">329 (17.6)</td>
<td colspan="1" rowspan="1" align="center">244 (15.8)</td>
<td colspan="1" rowspan="1" align="center">250 (16.3)</td>
<td colspan="1" rowspan="1" align="center">163 (12.5)</td>
<td colspan="1" rowspan="1" align="center">139 (11.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Heart failure</td>
<td colspan="1" rowspan="1" align="center">766 (20.7)</td>
<td colspan="1" rowspan="1" align="center">506 (16.4)</td>
<td colspan="1" rowspan="1" align="center">395 (15.4)</td>
<td colspan="1" rowspan="1" align="center">387 (21.2)</td>
<td colspan="1" rowspan="1" align="center">379 (20.3)</td>
<td colspan="1" rowspan="1" align="center">243 (15.7)</td>
<td colspan="1" rowspan="1" align="center">263 (17.1)</td>
<td colspan="1" rowspan="1" align="center">202 (15.5)</td>
<td colspan="1" rowspan="1" align="center">193 (15.3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> NYHA class I</td>
<td colspan="1" rowspan="1" align="center">202 (5.5)</td>
<td colspan="1" rowspan="1" align="center">104 (3.4)</td>
<td colspan="1" rowspan="1" align="center">42 (1.6)</td>
<td colspan="1" rowspan="1" align="center">100 (5.5)</td>
<td colspan="1" rowspan="1" align="center">102 (5.5)</td>
<td colspan="1" rowspan="1" align="center">47 (3.0)</td>
<td colspan="1" rowspan="1" align="center">57 (3.7)</td>
<td colspan="1" rowspan="1" align="center">22 (1.7)</td>
<td colspan="1" rowspan="1" align="center">20 (1.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> NYHA class II</td>
<td colspan="1" rowspan="1" align="center">447 (12.1)</td>
<td colspan="1" rowspan="1" align="center">341 (11.1)</td>
<td colspan="1" rowspan="1" align="center">303 (11.8)</td>
<td colspan="1" rowspan="1" align="center">223 (12.2)</td>
<td colspan="1" rowspan="1" align="center">224 (12.0)</td>
<td colspan="1" rowspan="1" align="center">168 (10.9)</td>
<td colspan="1" rowspan="1" align="center">173 (11.2)</td>
<td colspan="1" rowspan="1" align="center">155 (11.9)</td>
<td colspan="1" rowspan="1" align="center">148 (11.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> NYHA class III</td>
<td colspan="1" rowspan="1" align="center">106 (2.9)</td>
<td colspan="1" rowspan="1" align="center">58 (1.9)</td>
<td colspan="1" rowspan="1" align="center">50 (1.9)</td>
<td colspan="1" rowspan="1" align="center">56 (3.1)</td>
<td colspan="1" rowspan="1" align="center">50 (2.7)</td>
<td colspan="1" rowspan="1" align="center">25 (1.6)</td>
<td colspan="1" rowspan="1" align="center">33 (2.1)</td>
<td colspan="1" rowspan="1" align="center">25 (1.9)</td>
<td colspan="1" rowspan="1" align="center">25 (2.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Ischemic heart disease</td>
<td colspan="1" rowspan="1" align="center">2795 (75.7)</td>
<td colspan="1" rowspan="1" align="center">2264 (73.4)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">1386 (75.9)</td>
<td colspan="1" rowspan="1" align="center">1409 (75.5)</td>
<td colspan="1" rowspan="1" align="center">1131 (73.2)</td>
<td colspan="1" rowspan="1" align="center">1133 (73.7)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Stable angina</td>
<td colspan="1" rowspan="1" align="center">639 (17.3)</td>
<td colspan="1" rowspan="1" align="center">1178 (38.2)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">306 (16.7)</td>
<td colspan="1" rowspan="1" align="center">333 (17.9)</td>
<td colspan="1" rowspan="1" align="center">604 (39.1)</td>
<td colspan="1" rowspan="1" align="center">574 (37.3)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Asymptomatic (silent) cardiac ischemia</td>
<td colspan="1" rowspan="1" align="center">289 (7.8)</td>
<td colspan="1" rowspan="1" align="center">555 (18.0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">147 (8.0)</td>
<td colspan="1" rowspan="1" align="center">142 (7.6)</td>
<td colspan="1" rowspan="1" align="center">271 (17.5)</td>
<td colspan="1" rowspan="1" align="center">284 (18.5)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Unstable angina</td>
<td colspan="1" rowspan="1" align="center">283 (7.7)</td>
<td colspan="1" rowspan="1" align="center">497 (16.1)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">139 (7.6)</td>
<td colspan="1" rowspan="1" align="center">144 (7.7)</td>
<td colspan="1" rowspan="1" align="center">240 (15.5)</td>
<td colspan="1" rowspan="1" align="center">257 (16.7)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Non–ST-segment–elevation MI</td>
<td colspan="1" rowspan="1" align="center">599 (16.2)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">302 (16.5)</td>
<td colspan="1" rowspan="1" align="center">297 (15.9)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> ST-segment–elevation MI</td>
<td colspan="1" rowspan="1" align="center">869 (23.5)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">437 (23.9)</td>
<td colspan="1" rowspan="1" align="center">432 (23.2)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">PCI performed</td>
<td colspan="1" rowspan="1" align="center">1599 (43.3)</td>
<td colspan="1" rowspan="1" align="center">969 (31.4)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">790 (43.2)</td>
<td colspan="1" rowspan="1" align="center">809 (43.4)</td>
<td colspan="1" rowspan="1" align="center">476 (30.8)</td>
<td colspan="1" rowspan="1" align="center">493 (32.1)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">CABG performed</td>
<td colspan="1" rowspan="1" align="center">906 (24.5)</td>
<td colspan="1" rowspan="1" align="center">625 (20.3)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">438 (24.0)</td>
<td colspan="1" rowspan="1" align="center">468 (25.1)</td>
<td colspan="1" rowspan="1" align="center">311 (20.1)</td>
<td colspan="1" rowspan="1" align="center">314 (20.4)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Left ventricular systolic dysfunction</td>
<td colspan="1" rowspan="1" align="center">619 (16.8)</td>
<td colspan="1" rowspan="1" align="center">250 (8.1)</td>
<td colspan="1" rowspan="1" align="center">130 (5.1)</td>
<td colspan="1" rowspan="1" align="center">308 (16.9)</td>
<td colspan="1" rowspan="1" align="center">311 (16.7)</td>
<td colspan="1" rowspan="1" align="center">112 (7.2)</td>
<td colspan="1" rowspan="1" align="center">138 (9.0)</td>
<td colspan="1" rowspan="1" align="center">58 (4.5)</td>
<td colspan="1" rowspan="1" align="center">72 (5.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Left ventricular diastolic dysfunction</td>
<td colspan="1" rowspan="1" align="center">580 (15.7)</td>
<td colspan="1" rowspan="1" align="center">487 (15.8)</td>
<td colspan="1" rowspan="1" align="center">514 (20.0)</td>
<td colspan="1" rowspan="1" align="center">317 (17.4)</td>
<td colspan="1" rowspan="1" align="center">263 (14.1)</td>
<td colspan="1" rowspan="1" align="center">225 (14.6)</td>
<td colspan="1" rowspan="1" align="center">262 (17.0)</td>
<td colspan="1" rowspan="1" align="center">257 (19.8)</td>
<td colspan="1" rowspan="1" align="center">257 (20.3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Hypertension</td>
<td colspan="1" rowspan="1" align="center">3356 (90.9)</td>
<td colspan="1" rowspan="1" align="center">2815 (91.3)</td>
<td colspan="1" rowspan="1" align="center">2340 (91.2)</td>
<td colspan="1" rowspan="1" align="center">1662 (91.0)</td>
<td colspan="1" rowspan="1" align="center">1694 (90.8)</td>
<td colspan="1" rowspan="1" align="center">1403 (90.8)</td>
<td colspan="1" rowspan="1" align="center">1412 (91.8)</td>
<td colspan="1" rowspan="1" align="center">1185 (91.2)</td>
<td colspan="1" rowspan="1" align="center">1155 (91.3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Ischemic stroke</td>
<td colspan="1" rowspan="1" align="center">1038 (28.1)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">526 (28.8)</td>
<td colspan="1" rowspan="1" align="center">512 (27.5)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Transient ischemic attack</td>
<td colspan="1" rowspan="1" align="center">265 (7.2)</td>
<td colspan="1" rowspan="1" align="center">302 (9.8)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">146 (8.0)</td>
<td colspan="1" rowspan="1" align="center">119 (6.4)</td>
<td colspan="1" rowspan="1" align="center">164 (10.6)</td>
<td colspan="1" rowspan="1" align="center">138 (9.0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Hemorrhagic stroke</td>
<td colspan="1" rowspan="1" align="center">103 (2.8)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">50 (2.7)</td>
<td colspan="1" rowspan="1" align="center">53 (2.8)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Intracranial artery stenosis</td>
<td colspan="1" rowspan="1" align="center">80 (2.2)</td>
<td colspan="1" rowspan="1" align="center">30 (1.0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">37 (2.0)</td>
<td colspan="1" rowspan="1" align="center">43 (2.3)</td>
<td colspan="1" rowspan="1" align="center">9 (0.6)</td>
<td colspan="1" rowspan="1" align="center">21 (1.4)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Carotid artery stenosis</td>
<td colspan="1" rowspan="1" align="center">342 (9.3)</td>
<td colspan="1" rowspan="1" align="center">357 (11.6)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">162 (8.9)</td>
<td colspan="1" rowspan="1" align="center">180 (9.7)</td>
<td colspan="1" rowspan="1" align="center">170 (11.0)</td>
<td colspan="1" rowspan="1" align="center">187 (12.2)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Peripheral artery disease in lower extremities</td>
<td colspan="1" rowspan="1" align="center">404 (10.9)</td>
<td colspan="1" rowspan="1" align="center">763 (24.7)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">205 (11.2)</td>
<td colspan="1" rowspan="1" align="center">199 (10.7)</td>
<td colspan="1" rowspan="1" align="center">395 (25.6)</td>
<td colspan="1" rowspan="1" align="center">368 (23.9)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">&gt;50% stenosis of the coronary, carotid, or other arteries</td>
<td colspan="1" rowspan="1" align="center">1294 (35.0)</td>
<td colspan="1" rowspan="1" align="center">1084 (35.2)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">650 (35.6)</td>
<td colspan="1" rowspan="1" align="center">644 (34.5)</td>
<td colspan="1" rowspan="1" align="center">541 (35.0)</td>
<td colspan="1" rowspan="1" align="center">543 (35.3)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
<td colspan="1" rowspan="1" align="center">0 (0)</td>
</tr>
</tbody>
</table>
<div class="tableFooter"><div xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="footnote"><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">CABG
 indicates coronary artery bypass graft; CVD, cardiovascular disease; 
MI, myocardial infarction; NYHA, New York Heart Association; and PCI, 
percutaneous coronary intervention.</p></div></div>
</div>
<div id="acd3e3083" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e3083">Acknowledgments</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 authors thank all trial personnel and patients. Editorial and 
submission support, limited to formatting and collation of coauthor 
comments, was provided by Watermeadow Medical, an Ashfield Company, part
 of UDG Healthcare plc, funded by Novo Nordisk A/S. We thank Dr Hwee 
Teoh from St Michael’s Hospital for editorial assistance. Drs Verma, 
Marso, Ørsted, Fries, and Rasmussen had full access to the study data 
and take responsibility for its integrity and data analysis. The authors
 were fully responsible for all content and editorial decisions, 
involved at all stages of manuscript development, and have approved the 
final version. Drs Verma, Marso, and Bhatt wrote the first draft of the 
paper. Drs Nauck, Poulter, Bain, Buse, Pratley, Zinman, and Rasmussen 
were involved in the design, performance, and statistical analysis of 
the LEADER trial. All authors were involved in reviewing and 
interpreting the data and providing further comments and revisions. All 
authors approved the final version of the manuscript.</p>
<div class="articleInformation">
<div id="acd3e3091" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e3091">Sources of Funding</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">This study was funded by Novo Nordisk A/S.</p>
</div>
<div class="articleInformation">
<div id="acd3e3099" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e3099">Disclosures</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Dr
 Verma is President of the Canadian Medical and Surgical Knowledge 
Translation Research Group, a federally incorporated not-for-profit 
physician organization; holds a Tier 1 Canada Research Chair in 
Cardiovascular Surgery; and reports receiving research grants and/or 
speaking honoraria from Amgen, AstraZeneca, Bayer Healthcare, Boehringer
 Ingelheim, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, 
Servier, and Valeant. Dr Poulter is president of the International 
Society of Hypertension; has received personal speaker fees from 
Servier, Takeda, and Novo Nordisk A/S; is on advisory boards for 
AstraZeneca and Novo Nordisk A/S; and receives research grants for his 
research group relating to T2DM from Diabetes UK, the National Institute
 for Health Research Efficacy and Mechanism Evaluation, Julius Clinical,
 and the British Heart Foundation, with a pending grant from Novo 
Nordisk A/S. Dr Bhatt reports the following: advisory board, Cardax, 
Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado 
Biosciences; board of directors, Boston Veterans Affairs Research 
Institute and Society of Cardiovascular Patient Care; chair, American 
Heart Association Quality Oversight Committee; data monitoring 
committee, Baim Institute for Clinical Research (formerly Harvard 
Clinical Research Institute), Cleveland Clinic, Duke Clinical Research 
Institute, Mayo Clinic, Mount Sinai School of Medicine, and Population 
Health Research Institute; honoraria, American College of Cardiology 
(senior associate editor, <i>Clinical Trials and News</i>, ACC.org; 
vice-chair, ACC Accreditation Committee), Baim Institute for Clinical 
Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI 
clinical trial [Randomized Evaluation of Dual Antithrombotic Therapy 
with Dabigatran Versus Triple Therapy With Warfarin in Patients With 
Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary 
Intervention] steering committee funded by Boehringer Ingelheim); editor
 in chief, <i>Harvard Heart Letter</i>, Belvoir Publications; clinical trial steering committees, Duke Clinical Research Institute; editor in chief, <i>Journal of Invasive Cardiology</i>, HMP Global; guest editor and associate editor, <i>Journal of the American College of Cardiology</i>; clinical trial steering committee, Population Health Research Institute; chief medical editor, <i>Cardiology Today’s Intervention</i>,
 Slack Publications; secretary/treasurer, Society of Cardiovascular 
Patient Care; Continuing Medical Education steering committees, WebMD; 
deputy editor, <i>Clinical Cardiology</i>; chair, National 
Cardiovascular Data Registry–Acute Coronary Treatment and Interventions 
Outcomes Network Registry Steering Committee; chair, Veterans Affairs 
Clinical Assessment Reporting and Tracking Research and Publications 
Committee; research funding, Abbott, Amarin, Amgen, AstraZeneca, 
Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, 
Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, 
Regeneron, Roche, Sanofi Aventis, Synaptic, and The Medicines Company; 
royalties, Elsevier (editor, <i>Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease</i>);
 site coinvestigator, Biotronik, Boston Scientific, St Jude Medical (now
 Abbott), and Svelte; trustee, American College of Cardiology; and 
unfunded research, FlowCo, Merck, Novo Nordisk, PLx Pharma, and Takeda. 
Dr Bain reports research grants (includes principal investigator, 
collaborator, or consultant and pending grants, as well as grants 
already received) from Healthcare and Research Wales (Welsh Government) 
and Novo Nordisk A/S; other research support from Healthcare and 
Research Wales (Welsh Government) and infrastructure support; honoraria 
from Novo Nordisk A/S, Sanofi, Lilly, Boehringer Ingelheim, and Merck; 
and ownership interest in Glycosmedia (diabetes online news service). Dr
 Buse reports consulting fees paid to his institution and travel support
 from Novo Nordisk A/S, Eli Lilly, Bristol-Myers Squibb, GI Dynamics, 
Elcelyx, Merck, Metavention, vTv Therapeutics, PhaseBio, AstraZeneca, 
Dance Biopharm, Quest Diagnostics, Sanofi-Aventis, Lexicon 
Pharmaceuticals, Orexigen Therapeutics, Takeda Pharmaceuticals, Adocia, 
and Roche; grant support from Eli Lilly, Bristol-Myers Squibb, GI 
Dynamics, Merck, PhaseBio, AstraZeneca, Medtronic, Sanofi, Tolerex, 
Osiris Therapeutics, Halozyme Therapeutics, Johnson &amp; Johnson, 
Andromeda, Boehringer Ingelheim, GlaxoSmithKline, Astellas Pharma, 
MacroGenics, Intarcia Therapeutics, Lexicon, Senseonics, Scion 
NeuroStim, Orexigen Therapeutics, Takeda Pharmaceuticals, Theracos, 
Roche, and the National Institutes of Health (UL1TR002489); fees and 
stock options from PhaseBio and Mellitus Health; and boards of the 
AstraZeneca Healthcare Foundation and Bristol-Myers Squibb Together on 
Diabetes Foundation. Dr Leiter reports consultant and speaker fees from 
AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo 
Nordisk A/S, Sanofi, and Servier, as well as research grants or support 
from AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, 
Janssen, Merck, Novo Nordisk A/S, and Sanofi. Dr Nauck reports advisory 
boards or consultancy for AstraZeneca, Boehringer Ingelheim, Eli Lilly 
&amp; Co, Fractyl, GlaxoSmithKline, Menarini/Berlin Chemie, Merck, Sharp
 &amp; Dohme, and Novo Nordisk A/S, as well as speakers’ bureaus for 
AstraZeneca, Boehringer Ingelheim, Eli Lilly &amp; Co, Menarini/Berlin 
Chemie, Merck, Sharp &amp; Dohme, and Novo Nordisk A/S. His institution 
has received grant support from AstraZeneca, Eli Lilly &amp; Co, 
Menarini/Berlin-Chemie, Merck, Sharp &amp; Dohme, Novartis Pharma, and 
Novo Nordisk A/S. Dr Pratley reports research grants from Gilead 
Sciences, Lexicon Pharmaceuticals, Ligand Pharmaceuticals Inc, Lilly, 
Merck, Novo Nordisk A/S, Sanofi-Aventis US LLC, and Takeda; speaker fees
 from AstraZeneca, Novo Nordisk A/S, and Takeda; and consultant fees 
from AstraZeneca, Boehringer Ingelheim, Eisai, Inc, GlaxoSmithKline, 
Janssen Scientific Affairs LLC, Ligand Pharmaceuticals Inc, Lilly, 
Merck, Novo Nordisk A/S, Pfizer, and Takeda. All payments are made 
directly to his employer (Florida Hospital). Dr Zinman reports 
consulting fees from Merck, Novo Nordisk A/S, Sanofi-Aventis, Eli Lilly,
 AstraZeneca, Janssen, and Boehringer Ingelheim. Drs Ørsted, Rasmussen, 
and Monk Fries are Novo Nordisk A/S employees and shareholders. Dr Marso
 reports consulting fees from Novo Nordisk A/S and St Jude Medical and 
research support from Novo Nordisk A/S, Terumo, The Medicines Company, 
AstraZeneca, and Bristol-Myers Squibb.</p>
</div>
<h3 class="article-section__title to-section " id="d716891e250">Footnotes</h3>
<div class="NLM_author-notes">
<fn xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" fn-type="financial-disclosure" id="fn01"><p>Sources of Funding, see page 2893</p></fn><fn xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" fn-type="other" id="fn02"><p>Continuing medical education (CME) credit is available for this article. Go to <a class="references__uri" href="http://cme.ahajournals.org/">http://cme.ahajournals.org</a> to take the quiz.</p></fn><fn xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" fn-type="supplementary-material" id="fn03"><p>The online-only Data Supplement, podcast, and transcript are available with this article at <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.034516">https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.034516</a>.</p></fn><fn xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" fn-type="other" id="fn04"><p><a class="references__uri" href="https://www.ahajournals.org/journal/circ">https://www.ahajournals.org/journal/circ</a></p></fn><div class="NLM_corresp">Steven P. Marso, MD, Research Medical Center, 2316 E Meyer Blvd, Kansas City, MO 64132. Email <a class="references__email" href="mailto:Steve.Marso@HCAhealthcare.com"><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="nobrWithWbr">Steve.<wbr xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Marso@HCAhealthcare.<wbr xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">com</wbr></wbr></span></a>
</div>
</div>
<div class="article__references">
<p class="explanation__text"></p>
<h2 class="article-section__title to-section" id="d716891e2102">References</h2>
<ul class="rlist separator">
<li id="R1" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R1R" class="tab-link-return ref__number"><span class="label">1. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Cavender MA, Steg PG, Smith SC, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL</person-group>; REACH Registry Investigators. <span class="references__article-title">Impact
 of diabetes mellitus on hospitalization for heart failure, 
cardiovascular events, and death: outcomes at 4 years from the Reduction
 of Atherothrombosis for Continued Health (REACH) registry.</span><span class="references__source"><strong>Circulation</strong></span>. <span class="references__year">2015</span>; 132:923–931. doi: 10.1161/CIRCULATIONAHA.114.014796<span class="references__suffix"><a href="https://www.ahajournals.org/doi/10.1161/circulationaha.114.014796" onclick="newWindow(this.href);return false" target="_blank">Link</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=132&amp;publication_year=2015&amp;pages=923-931&amp;journal=Circulation&amp;author=MA+Cavender&amp;author=PG+Steg&amp;author=SC+Smith&amp;author=K+Eagle&amp;author=EM+Ohman&amp;author=S+Goto&amp;author=J+Kuder&amp;author=K+Im&amp;author=PW+Wilson&amp;author=DL+Bhatt&amp;title=Impact+of+diabetes+mellitus+on+hospitalization+for+heart+failure%2C+cardiovascular+events%2C+and+death%3A+outcomes+at+4+years+from+the+Reduction+of+Atherothrombosis+for+Continued+Health+%28REACH%29+registry." target="_blank">Google Scholar</a></span></span></li>
<li id="R2" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R2R" class="tab-link-return ref__number"><span class="label">2. </span></a>Centers for Disease Control and Prevention. <span class="references__article-title">National diabetes statistics report.</span><span class="references__year">2014</span>. <a class="references__uri" href="https://www.cdc.gov/diabetes/pdfs/data/2014-report-estimates-of-diabetes-and-its-burden-in-the-united-states.pdf">https://www.cdc.gov/diabetes/pdfs/data/2014-report-estimates-of-diabetes-and-its-burden-in-the-united-states.pdf</a>. Accessed January 18, 2017.<span class="references__suffix"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2014&amp;title=National+diabetes+statistics+report." target="_blank">Google Scholar</a></span></span></li>
<li id="R3" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R3R" class="tab-link-return ref__number"><span class="label">3. </span></a>Emerging Risk Factors Collaboration, <person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Sarwar
 N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson
 E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells
 L, Thompson A, Sattar N, White IR, Ray KK, Danesh J</person-group>. <span class="references__article-title">Diabetes
 mellitus, fasting blood glucose concentration, and risk of vascular 
disease: a collaborative meta-analysis of 102 prospective studies.</span><span class="references__source"><strong>Lancet</strong></span>. <span class="references__year">2010</span>; 375:2215–2222. doi: 10.1016/S0140-6736(10)60484–9<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_4_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.1016%2FS0140-6736%2810%2960484-9" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_4_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=20609967" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=375&amp;publication_year=2010&amp;pages=2215-2222&amp;journal=Lancet&amp;author=N+Sarwar&amp;author=P+Gao&amp;author=SR+Seshasai&amp;author=R+Gobin&amp;author=S+Kaptoge&amp;author=E+Di+Angelantonio&amp;author=E+Ingelsson&amp;author=DA+Lawlor&amp;author=E+Selvin&amp;author=M+Stampfer&amp;author=CD+Stehouwer&amp;author=S+Lewington&amp;author=L+Pennells&amp;author=A+Thompson&amp;author=N+Sattar&amp;author=IR+White&amp;author=KK+Ray&amp;author=J+Danesh&amp;title=Diabetes+mellitus%2C+fasting+blood+glucose+concentration%2C+and+risk+of+vascular+disease%3A+a+collaborative+meta-analysis+of+102+prospective+studies." target="_blank">Google Scholar</a></span></span></li>
<li id="R4" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R4R" class="tab-link-return ref__number"><span class="label">4. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E, Sabatine MS, Steg PG</person-group>. <span class="references__article-title">Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54.</span><span class="references__source"><strong>J Am Coll Cardiol</strong></span>. <span class="references__year">2016</span>; 67:2732–2740. doi: 10.1016/j.jacc.2016.03.529<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_5_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.1016%2Fj.jacc.2016.03.529" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_5_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=27046160" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=67&amp;publication_year=2016&amp;pages=2732-2740&amp;journal=J+Am+Coll+Cardiol&amp;author=DL+Bhatt&amp;author=MP+Bonaca&amp;author=S+Bansilal&amp;author=DJ+Angiolillo&amp;author=M+Cohen&amp;author=RF+Storey&amp;author=K+Im&amp;author=SA+Murphy&amp;author=P+Held&amp;author=E+Braunwald&amp;author=MS+Sabatine&amp;author=PG+Steg&amp;title=Reduction+in+ischemic+events+with+ticagrelor+in+diabetic+patients+with+prior+myocardial+infarction+in+PEGASUS-TIMI+54." target="_blank">Google Scholar</a></span></span></li>
<li id="R5" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R5R" class="tab-link-return ref__number"><span class="label">5. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Bhatt DL</person-group>. <span class="references__article-title">Antiplatelet therapy following myocardial infarction in patients with diabetes.</span><span class="references__source"><strong>JAMA</strong></span>. <span class="references__year">2012</span>; 308:921–922. doi: 10.1001/2012.jama.11467<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_6_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.1001%2F2012.jama.11467" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_6_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=22948703" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=308&amp;publication_year=2012&amp;pages=921-922&amp;journal=JAMA&amp;author=DL+Bhatt&amp;title=Antiplatelet+therapy+following+myocardial+infarction+in+patients+with+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li id="R6" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R6R" class="tab-link-return ref__number"><span class="label">6. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Hussain MA, Al-Omran M, Mamdani M</person-group>. <span class="references__article-title">Efficacy
 of a guideline-recommended risk-reduction program to improve 
cardiovascular and limb outcomes in patients with peripheral arterial 
disease.</span><span class="references__source"><strong>J Vasc Surg</strong></span>. <span class="references__year">2016</span>; 64:535. doi: 10.1016/j.jvs.2016.06.055<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_7_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.1016%2Fj.jvs.2016.06.055" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=64&amp;publication_year=2016&amp;pages=535&amp;journal=J+Vasc+Surg&amp;author=MA+Hussain&amp;author=M+Al-Omran&amp;author=M+Mamdani&amp;title=Efficacy+of+a+guideline-recommended+risk-reduction+program+to+improve+cardiovascular+and+limb+outcomes+in+patients+with+peripheral+arterial+disease." target="_blank">Google Scholar</a></span></span></li>
<li id="R7" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R7R" class="tab-link-return ref__number"><span class="label">7. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Burrows NR, Li Y, Gregg EW, Geiss LS</person-group>. <span class="references__article-title">Declining
 rates of hospitalization for selected cardiovascular disease conditions
 among adults aged ≥35 years with diagnosed diabetes, U.S., 1998–2014.</span><span class="references__source"><strong>Diabetes Care</strong></span>. <span class="references__year">2018</span>; 41:293–302. doi: 10.2337/dc17-1259<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_8_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.2337%2Fdc17-1259" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_8_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=29150530" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=41&amp;publication_year=2018&amp;pages=293-302&amp;journal=Diabetes+Care&amp;author=NR+Burrows&amp;author=Y+Li&amp;author=EW+Gregg&amp;author=LS+Geiss&amp;title=Declining+rates+of+hospitalization+for+selected+cardiovascular+disease+conditions+among+adults+aged+%E2%89%A535+years+with+diagnosed+diabetes%2C+U.S.%2C+1998%E2%80%932014." target="_blank">Google Scholar</a></span></span></li>
<li id="R8" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R8R" class="tab-link-return ref__number"><span class="label">8. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Marso
 SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, 
Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, 
Zinman B, Bergenstal RM, Buse JB</person-group>; LEADER Steering Committee; LEADER Trial Investigators. <span class="references__article-title">Liraglutide and cardiovascular outcomes in type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2016a</span>; 375:311–322. doi: 10.1056/NEJMoa1603827<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_9_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.1056%2FNEJMoa1603827" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_9_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=27295427" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=375&amp;publication_year=2016a&amp;pages=311-322&amp;journal=N+Engl+J+Med&amp;author=SP+Marso&amp;author=GH+Daniels&amp;author=K+Brown-Frandsen&amp;author=P+Kristensen&amp;author=JF+Mann&amp;author=MA+Nauck&amp;author=SE+Nissen&amp;author=S+Pocock&amp;author=NR+Poulter&amp;author=LS+Ravn&amp;author=WM+Steinberg&amp;author=M+Stockner&amp;author=B+Zinman&amp;author=RM+Bergenstal&amp;author=JB+Buse&amp;title=Liraglutide+and+cardiovascular+outcomes+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li id="R9" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R9R" class="tab-link-return ref__number"><span class="label">9. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Bhatt
 DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW, 
Alberts MJ, D’Agostino R, Liau CS, Mas JL, Röther J, Smith SC, Salette 
G, Contant CF, Massaro JM, Steg PG</person-group>; REACH Registry Investigators. <span class="references__article-title">Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.</span><span class="references__source"><strong>JAMA</strong></span>. <span class="references__year">2010</span>; 304:1350–1357. doi: 10.1001/jama.2010.1322<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_10_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.1001%2Fjama.2010.1322" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_10_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=20805624" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=304&amp;publication_year=2010&amp;pages=1350-1357&amp;journal=JAMA&amp;author=DL+Bhatt&amp;author=KA+Eagle&amp;author=EM+Ohman&amp;author=AT+Hirsch&amp;author=S+Goto&amp;author=EM+Mahoney&amp;author=PW+Wilson&amp;author=MJ+Alberts&amp;author=R+D%E2%80%99Agostino&amp;author=CS+Liau&amp;author=JL+Mas&amp;author=J+R%C3%B6ther&amp;author=SC+Smith&amp;author=G+Salette&amp;author=CF+Contant&amp;author=JM+Massaro&amp;author=PG+Steg&amp;title=Comparative+determinants+of+4-year+cardiovascular+event+rates+in+stable+outpatients+at+risk+of+or+with+atherothrombosis." target="_blank">Google Scholar</a></span></span></li>
<li id="R10" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R10R" class="tab-link-return ref__number"><span class="label">10. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Marso
 SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, 
Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, 
Buse JB</person-group>. <span class="references__article-title">Design of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial.</span><span class="references__source"><strong>Am Heart J</strong></span>. <span class="references__year">2013</span>; 166:823–830.e5. doi: 10.1016/j.ahj.2013.07.012<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_11_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.1016%2Fj.ahj.2013.07.012" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_11_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=24176437" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=166&amp;publication_year=2013&amp;pages=823-830.e5&amp;journal=Am+Heart+J&amp;author=SP+Marso&amp;author=NR+Poulter&amp;author=SE+Nissen&amp;author=MA+Nauck&amp;author=B+Zinman&amp;author=GH+Daniels&amp;author=S+Pocock&amp;author=WM+Steinberg&amp;author=RM+Bergenstal&amp;author=JF+Mann&amp;author=LS+Ravn&amp;author=KB+Frandsen&amp;author=AC+Moses&amp;author=JB+Buse&amp;title=Design+of+the+Liraglutide+Effect+and+Action+in+Diabetes%3A+Evaluation+of+Cardiovascular+Outcome+Results+%28LEADER%29+trial." target="_blank">Google Scholar</a></span></span></li>
<li id="R11" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R11R" class="tab-link-return ref__number"><span class="label">11. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Fine JP, Gray RJ</person-group>. <span class="references__article-title">A proportional hazards model for the subdistribution of a competing risk.</span><span class="references__source"><strong>J Am Stat Assoc</strong></span>. <span class="references__year">1999</span>; 94:496–509. doi: 10.2307/2670170.<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_12_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.1080%2F01621459.1999.10474144" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=94&amp;publication_year=1999&amp;pages=496-509&amp;journal=J+Am+Stat+Assoc&amp;author=JP+Fine&amp;author=RJ+Gray&amp;title=A+proportional+hazards+model+for+the+subdistribution+of+a+competing+risk." target="_blank">Google Scholar</a></span></span></li>
<li id="R12" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R12R" class="tab-link-return ref__number"><span class="label">12. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Altman DG, Andersen PK</person-group>. <span class="references__article-title">Calculating the number needed to treat for trials where the outcome is time to an event.</span><span class="references__source"><strong>BMJ</strong></span>. <span class="references__year">1999</span>; 319:1492–1495.<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_13_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.1136%2Fbmj.319.7223.1492" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_13_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10582940" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=319&amp;publication_year=1999&amp;pages=1492-1495&amp;journal=BMJ&amp;author=DG+Altman&amp;author=PK+Andersen&amp;title=Calculating+the+number+needed+to+treat+for+trials+where+the+outcome+is+time+to+an+event." target="_blank">Google Scholar</a></span></span></li>
<li id="R13" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R13R" class="tab-link-return ref__number"><span class="label">13. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Verma
 S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulter 
NR, Pratley RE, Zinman B, Michelsen MM, Monk Fries T, Rasmussen S, 
Leiter LA</person-group>; LEADER Publication Committee on behalf of the LEADER Trial Investigators. <span class="references__article-title">Effect
 of liraglutide on cardiovascular events in patients with type 2 
diabetes mellitus and polyvascular disease: results of the LEADER Trial.</span><span class="references__source"><strong>Circulation</strong></span>. <span class="references__year">2018</span>; 137:2179–2183. doi: 10.1161/CIRCULATIONAHA.118.033898<span class="references__suffix"><a href="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.033898" onclick="newWindow(this.href);return false" target="_blank">Link</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=137&amp;publication_year=2018&amp;pages=2179-2183&amp;journal=Circulation&amp;author=S+Verma&amp;author=DL+Bhatt&amp;author=SC+Bain&amp;author=JB+Buse&amp;author=JFE+Mann&amp;author=SP+Marso&amp;author=MA+Nauck&amp;author=NR+Poulter&amp;author=RE+Pratley&amp;author=B+Zinman&amp;author=MM+Michelsen&amp;author=T+Monk+Fries&amp;author=S+Rasmussen&amp;author=LA+Leiter&amp;title=Effect+of+liraglutide+on+cardiovascular+events+in+patients+with+type+2+diabetes+mellitus+and+polyvascular+disease%3A+results+of+the+LEADER+Trial." target="_blank">Google Scholar</a></span></span></li>
<li id="R14" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R14R" class="tab-link-return ref__number"><span class="label">14. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Udell
 JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, 
Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine MS, Braunwald E,
 Bhatt DL</person-group>. <span class="references__article-title">Long-term
 dual antiplatelet therapy for secondary prevention of cardiovascular 
events in the subgroup of patients with previous myocardial infarction: a
 collaborative meta-analysis of randomized trials.</span><span class="references__source"><strong>Eur Heart J</strong></span>. <span class="references__year">2016</span>; 37:390–399. doi: 10.1093/eurheartj/ehv443<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_15_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=26324537" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=37&amp;publication_year=2016&amp;pages=390-399&amp;journal=Eur+Heart+J&amp;author=JA+Udell&amp;author=MP+Bonaca&amp;author=JP+Collet&amp;author=AM+Lincoff&amp;author=DJ+Kereiakes&amp;author=F+Costa&amp;author=CW+Lee&amp;author=L+Mauri&amp;author=M+Valgimigli&amp;author=SJ+Park&amp;author=G+Montalescot&amp;author=MS+Sabatine&amp;author=E+Braunwald&amp;author=DL+Bhatt&amp;title=Long-term+dual+antiplatelet+therapy+for+secondary+prevention+of+cardiovascular+events+in+the+subgroup+of+patients+with+previous+myocardial+infarction%3A+a+collaborative+meta-analysis+of+randomized+trials." target="_blank">Google Scholar</a></span></span></li>
<li id="R15" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R15R" class="tab-link-return ref__number"><span class="label">15. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Palmerini
 T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres
 F, Abizaid A, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Genereux P, 
Bhatt DL, Orlandi C, De Servi S, Petrou M, Rapezzi C, Stone GW</person-group>. <span class="references__article-title">Mortality
 in patients treated with extended duration dual antiplatelet therapy 
after drug-eluting stent implantation: a pairwise and bayesian network 
meta-analysis of randomised trials.</span><span class="references__source"><strong>Lancet</strong></span>. <span class="references__year">2015</span>; 385:2371–2382. doi: 10.1016/S0140-6736(15)60263-X<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_16_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.1016%2FS0140-6736%2815%2960263-X" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_16_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=25777667" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=385&amp;publication_year=2015&amp;pages=2371-2382&amp;journal=Lancet&amp;author=T+Palmerini&amp;author=U+Benedetto&amp;author=L+Bacchi-Reggiani&amp;author=D+Della+Riva&amp;author=G+Biondi-Zoccai&amp;author=F+Feres&amp;author=A+Abizaid&amp;author=MK+Hong&amp;author=BK+Kim&amp;author=Y+Jang&amp;author=HS+Kim&amp;author=KW+Park&amp;author=P+Genereux&amp;author=DL+Bhatt&amp;author=C+Orlandi&amp;author=S+De+Servi&amp;author=M+Petrou&amp;author=C+Rapezzi&amp;author=GW+Stone&amp;title=Mortality+in+patients+treated+with+extended+duration+dual+antiplatelet+therapy+after+drug-eluting+stent+implantation%3A+a+pairwise+and+bayesian+network+meta-analysis+of+randomised+trials." target="_blank">Google Scholar</a></span></span></li>
<li id="R16" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R16R" class="tab-link-return ref__number"><span class="label">16. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Verma S, Goodman SG, Mehta SR, Latter DA, Ruel M, Gupta M, Yanagawa B, Al-Omran M, Gupta N, Teoh H, Friedrich JO</person-group>. <span class="references__article-title">Should
 dual antiplatelet therapy be used in patients following coronary artery
 bypass surgery? A meta-analysis of randomized controlled trials.</span><span class="references__source"><strong>BMC Surg</strong></span>. <span class="references__year">2015</span>; 15:112. doi: 10.1186/s12893-015-0096-z<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_17_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.1186%2Fs12893-015-0096-z" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_17_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=26467661" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=15&amp;publication_year=2015&amp;pages=112&amp;journal=BMC+Surg&amp;author=S+Verma&amp;author=SG+Goodman&amp;author=SR+Mehta&amp;author=DA+Latter&amp;author=M+Ruel&amp;author=M+Gupta&amp;author=B+Yanagawa&amp;author=M+Al-Omran&amp;author=N+Gupta&amp;author=H+Teoh&amp;author=JO+Friedrich&amp;title=Should+dual+antiplatelet+therapy+be+used+in+patients+following+coronary+artery+bypass+surgery%3F+A+meta-analysis+of+randomized+controlled+trials." target="_blank">Google Scholar</a></span></span></li>
<li id="R17" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R17R" class="tab-link-return ref__number"><span class="label">17. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Sabatine
 MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, Kuder 
JF, Murphy SA, Wiviott SD, Kurtz C, Honarpour N, Keech AC, Sever PS, 
Pedersen TR</person-group>. <span class="references__article-title">Clinical benefit of evolocumab by severity and extent of coronary artery disease: an analysis from FOURIER.</span><span class="references__source"><strong>Circulation</strong></span>. <span class="references__year">2018</span>; 138:756–766. doi: 10.1161/CIRCULATIONAH.<span class="references__suffix"><a href="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.034309" onclick="newWindow(this.href);return false" target="_blank">Link</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=138&amp;publication_year=2018&amp;pages=756-766&amp;journal=Circulation&amp;author=MS+Sabatine&amp;author=GM+De+Ferrari&amp;author=RP+Giugliano&amp;author=K+Huber&amp;author=BS+Lewis&amp;author=J+Ferreira&amp;author=JF+Kuder&amp;author=SA+Murphy&amp;author=SD+Wiviott&amp;author=C+Kurtz&amp;author=N+Honarpour&amp;author=AC+Keech&amp;author=PS+Sever&amp;author=TR+Pedersen&amp;title=Clinical+benefit+of+evolocumab+by+severity+and+extent+of+coronary+artery+disease%3A+an+analysis+from+FOURIER." target="_blank">Google Scholar</a></span></span></li>
<li id="R18" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R18R" class="tab-link-return ref__number"><span class="label">18. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Holman
 RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, 
Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, 
Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF</person-group>; EXSCEL Study Group. <span class="references__article-title">Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2017</span>; 377:1228–1239. doi: 10.1056/NEJMoa1612917.<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_19_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.1056%2FNEJMoa1612917" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_19_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=28910237" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=377&amp;publication_year=2017&amp;pages=1228-1239&amp;journal=N+Engl+J+Med&amp;author=RR+Holman&amp;author=MA+Bethel&amp;author=RJ+Mentz&amp;author=VP+Thompson&amp;author=Y+Lokhnygina&amp;author=JB+Buse&amp;author=JC+Chan&amp;author=J+Choi&amp;author=SM+Gustavson&amp;author=N+Iqbal&amp;author=AP+Maggioni&amp;author=SP+Marso&amp;author=P+%C3%96hman&amp;author=NJ+Pagidipati&amp;author=N+Poulter&amp;author=A+Ramachandran&amp;author=B+Zinman&amp;author=AF+Hernandez&amp;title=Effects+of+once-weekly+exenatide+on+cardiovascular+outcomes+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li id="R19" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R19R" class="tab-link-return ref__number"><span class="label">19. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR</person-group>; CANVAS Program Collaborative Group. <span class="references__article-title">Canagliflozin
 for primary and secondary prevention of cardiovascular events: results 
from the CANVAS program (Canagliflozin Cardiovascular Assessment Study).</span><span class="references__source"><strong>Circulation</strong></span>. <span class="references__year">2018</span>; 137:323–334. doi: 10.1161/CIRCULATIONAHA.117.032038<span class="references__suffix"><a href="https://www.ahajournals.org/doi/10.1161/circulationaha.117.032038" onclick="newWindow(this.href);return false" target="_blank">Link</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=137&amp;publication_year=2018&amp;pages=323-334&amp;journal=Circulation&amp;author=KW+Mahaffey&amp;author=B+Neal&amp;author=V+Perkovic&amp;author=D+de+Zeeuw&amp;author=G+Fulcher&amp;author=N+Erondu&amp;author=W+Shaw&amp;author=E+Fabbrini&amp;author=T+Sun&amp;author=Q+Li&amp;author=M+Desai&amp;author=DR+Matthews&amp;title=Canagliflozin+for+primary+and+secondary+prevention+of+cardiovascular+events%3A+results+from+the+CANVAS+program+%28Canagliflozin+Cardiovascular+Assessment+Study%29." target="_blank">Google Scholar</a></span></span></li>
<li id="R20" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R20R" class="tab-link-return ref__number"><span class="label">20. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Marso
 SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I,
 Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, 
Pettersson J, Vilsbøll T</person-group>; SUSTAIN-6 Investigators. <span class="references__article-title">Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2016</span>; 375:1834–1844. doi: 10.1056/NEJMoa1607141<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_21_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=10.1056%2FNEJMoa1607141" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_21_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.034516&amp;key=27633186" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=375&amp;publication_year=2016&amp;pages=1834-1844&amp;journal=N+Engl+J+Med&amp;author=SP+Marso&amp;author=SC+Bain&amp;author=A+Consoli&amp;author=FG+Eliaschewitz&amp;author=E+J%C3%B3dar&amp;author=LA+Leiter&amp;author=I+Lingvay&amp;author=J+Rosenstock&amp;author=J+Seufert&amp;author=ML+Warren&amp;author=V+Woo&amp;author=O+Hansen&amp;author=AG+Holst&amp;author=J+Pettersson&amp;author=T+Vilsb%C3%B8ll&amp;title=Semaglutide+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li id="R21" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R21R" class="tab-link-return ref__number"><span class="label">21. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ</person-group>. <span class="references__article-title">Cardiovascular
 actions and clinical outcomes with glucagon-like peptide-1 receptor 
agonists and dipeptidyl peptidase-4 inhibitors.</span><span class="references__source"><strong>Circulation</strong></span>. <span class="references__year">2017</span>; 136:849–870. doi: 10.1161/CIRCULATIONAHA.117.028136<span class="references__suffix"><a href="https://www.ahajournals.org/doi/10.1161/circulationaha.117.028136" onclick="newWindow(this.href);return false" target="_blank">Link</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=136&amp;publication_year=2017&amp;pages=849-870&amp;journal=Circulation&amp;author=MA+Nauck&amp;author=JJ+Meier&amp;author=MA+Cavender&amp;author=M+Abd+El+Aziz&amp;author=DJ+Drucker&amp;title=Cardiovascular+actions+and+clinical+outcomes+with+glucagon-like+peptide-1+receptor+agonists+and+dipeptidyl+peptidase-4+inhibitors." target="_blank">Google Scholar</a></span></span></li>
</ul>
</div>
</div>
